{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "a6e8cc8d",
   "metadata": {},
   "source": [
    "### Connect with NCBI Pubmed\n",
    "* Provide a valid email address"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "010a47b1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. Cancer. 2025 Apr 15;131(8):e35840. doi: 10.1002/cncr.35840.\n",
      "\n",
      "Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or \n",
      "refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.\n",
      "\n",
      "Goulart H(1), Kantarjian H(2), Borthakur G(2), Daver N(2), DiNardo CD(2), \n",
      "Jabbour E(2), Pemmaraju N(2), Alvarado Y(2), Atluri H(1), Yilmaz M(2), Haddad \n",
      "FG(2), Marx KR(3), Rausch C(3), Loghavi S(4), Jain N(2), Garcia-Manero G(2), \n",
      "Ravandi-Kashani F(2), Kadia TM(2).\n",
      "\n",
      "Author information:\n",
      "(1)Division of Cancer Medicine, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "(2)Department of Leukemia, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(3)Division of Pharmacy, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(4)Department of Hematopathology, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "\n",
      "BACKGROUND: The treatment of relapsed and/or refractory (R/R) acute myeloid \n",
      "leukemia (AML) remains challenging because of poor responses to chemotherapy. \n",
      "Efforts to improve outcomes have included the use of high-dose cytarabine in \n",
      "combination with nucleoside analogs, such as cladribine. The authors evaluated \n",
      "combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 \n",
      "patients with R/R AML.\n",
      "METHODS: Patients received induction with cladribine 5 mg/m2 intravenously (days \n",
      "1-5), cytarabine 1000 mg/m2 intravenously (days 1-5), and idarubicin 10 mg/m2 \n",
      "intravenously (days 1-3; CLIA). Sorafenib 400 mg twice daily (days 1-14) was \n",
      "added for FLT3-mutated AML.\n",
      "RESULTS: The composite response rate (complete remission [CR] plus complete \n",
      "remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) \n",
      "patients (n = 35) had a CR/CRi rate of 49%. After a 61-month median follow-up, \n",
      "the median overall survival (OS) was 7.9 months, with a median relapse-free \n",
      "survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients \n",
      "was 12 months, with a median RFS of 10.3 months. For those who received CLIA \n",
      "with sorafenib (n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and \n",
      "median RFS was 3.8 months. Landmark analysis demonstrated superior OS for \n",
      "patients who proceeded to transplantation compared with patients who did not \n",
      "(median OS, 78 vs. 8.8 months, respectively; p < .001). The 4-week and 8-week \n",
      "mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were \n",
      "related to infection and elevated liver function tests.\n",
      "CONCLUSIONS: CLIA is effective for patients with R/R AML and offers a safety \n",
      "profile similar to that of other intensive regimens (ClinicalTrials.gov \n",
      "identifier NCT02115295).\n",
      "\n",
      "© 2025 American Cancer Society.\n",
      "\n",
      "DOI: 10.1002/cncr.35840\n",
      "PMID: 40193193 [Indexed for MEDLINE]\n",
      "\n",
      "\n",
      "2. Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338241312436. doi: \n",
      "10.1177/15330338241312436. Epub 2025 Mar 27.\n",
      "\n",
      "Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte \n",
      "Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute \n",
      "Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II \n",
      "Study.\n",
      "\n",
      "Luo B(1), Tan X(1), Zhang Y(1), Hu X(1), Zeng H(1), Xiao H(1), Lou S(1), Zhou \n",
      "K(1).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Hematology, The Second Affiliated Hospital, Chongqing Medical \n",
      "University, Jiangnan, Chongqing, 400000, China.\n",
      "\n",
      "BackgroundEffective treatment options are limited for elderly patients with \n",
      "acute myeloid leukemia (AML). A prospective phase II study was conducted to \n",
      "investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) \n",
      "combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating \n",
      "factor (G-CSF) in newly diagnosed older and unfit AML patients.MethodsTwenty-two \n",
      "patients were enrolled and deemed evaluable. The study included one cycle of \n",
      "induction and four cycles of consolidation, followed by maintenance \n",
      "therapy.ResultsThe median age of enrolled patients was 71.5 years (range, 63 to \n",
      "82 years), and 16 patients (72.7%) were over 70 years of age. The overall \n",
      "response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete \n",
      "remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first \n",
      "induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) \n",
      "relapsed, with a median time to relapse of 12.3 months. The median duration of \n",
      "response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall \n",
      "survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median \n",
      "progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). \n",
      "Common grade 3 or greater adverse events included febrile neutropenia (77.8%) \n",
      "and infection (63.6%), with pneumonia being the most common (10, 45.5%). There \n",
      "was one death (4.5%) within 30 days.ConclusionThe combination of PLD, LDAC, and \n",
      "G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early \n",
      "mortality, providing an attractive treatment option for newly diagnosed elderly \n",
      "and unfit AML patients.\n",
      "\n",
      "DOI: 10.1177/15330338241312436\n",
      "PMCID: PMC11952034\n",
      "PMID: 40147876 [Indexed for MEDLINE]\n"
     ]
    }
   ],
   "source": [
    "from Bio import Entrez\n",
    "\n",
    "## Provide your email for NCBI\n",
    "Entrez.email = \"qwei@systemsbiology.org\"\n",
    "\n",
    "## Search PubMed for articles related to \"Acute Myeloid Leukemia\"\n",
    "## API documents: https://www.ncbi.nlm.nih.gov/books/NBK25499/#chapter4.ESearch\n",
    "## retstart: Sequential index of the first UID in the retrieved set to be shown in the XML output (default = 0)\n",
    "## retmax: Total number of UIDs from the retrieved set to be shown in the XML output (default = 20)\n",
    "## Note: For PubMed, ESearch can only retrieve the first 10,000 records matching the query. \n",
    "##To obtain more than 10,000 PubMed records, consider using <EDirect> that contains \n",
    "## additional logic to batch PubMed search results automatically so that an arbitrary number can be retrieved\n",
    "\n",
    "search_term = \"Acute Myeloid Leukemia[Title/Abstract] AND clinical trial[Publication Type]\"\n",
    "handle = Entrez.esearch(db=\"pubmed\", term=search_term, retmax=2, restart=0)\n",
    "record = Entrez.read(handle)\n",
    "id_list = record[\"IdList\"]\n",
    "\n",
    "## Fetch the details (abstracts) for the articles\n",
    "## retmode: Retrieval mode. This parameter specifies the data format of the records returned, such as plain text, \n",
    "## HMTL or XML. See Table 1 for a full list of allowed values for each database.\n",
    "## Table 1: https://www.ncbi.nlm.nih.gov/books/NBK25499/table/chapter4.T._valid_values_of__retmode_and/?report=objectonly\n",
    "\n",
    "handle = Entrez.efetch(db=\"pubmed\", id=id_list, rettype=\"abstract\", retmode=\"text\")\n",
    "abstracts = handle.read()\n",
    "print(abstracts)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a1dc3555",
   "metadata": {},
   "source": [
    "Load the total results (limited to only clinical trial) extracted using eDirect from Pubmed\n",
    "* esearch -db pubmed -query \"Acute Myeloid Leukemia[Title/Abstract] AND clinical trial[Publication Type]\" | efetch -format abstract > AML_Pubmed_abstracts_only_clinical_trial.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "83a571be",
   "metadata": {},
   "outputs": [],
   "source": [
    "## Notice!! Please change the file path of following codes into your own\n",
    "extracted_pubmed_file_path = '/Users/Weiqi0/ISB_working/Ilya_lab/Translator/Pharmagenomics_KG/Pubmed_query_results/'\n",
    "\n",
    "\n",
    "import os\n",
    "file_path = 'AML_Pubmed_abstracts_only_clinical_trial.txt'\n",
    "if os.path.exists(extracted_pubmed_file_path + file_path):\n",
    "    with open(extracted_pubmed_file_path + file_path, 'r') as file:\n",
    "        content = file.read()\n",
    "#         print(content)\n",
    "else:\n",
    "    print(f\"Error: File '{file_path}' not found.\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9c84e488",
   "metadata": {},
   "source": [
    "Load the pre-trained LLM model and try extracting info from the extracted abstract\n",
    "* Based on Ollama platform\n",
    "* selected a variant of DeepSeek\n",
    "* Pre-requirements are here: https://docs.google.com/document/d/1qyxAB0aZqSJWEu04XcsgkfoMKUkZVBRsfbxyMGTU1Z8/edit?tab=t.0\n",
    "* ollama.chat() parameters:\n",
    "* model = : load the pulled LLM model\n",
    "* messages = : the list of messages represents the history of a conversation between the user and the model\n",
    "    * role = : \n",
    "    * what the user asks is represented by the messages with role = user\n",
    "    * what the model answers is represented by the messages with role = assistant\n",
    "    * finally, the first message is usually a message with role = system which describes how the model should behave when providing an answer. \n",
    "    * Notice that the chat endpoint does not have a dedicated System parameter: that’s because that’s the job of the first message you send)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "eb1d9715",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "Okay, so I need to explain Newton's Second Law of Motion. Hmm, let me start by recalling what I know about it. I remember that Newton had three laws of motion, and the second one is often the most talked about. It has something to do with force, mass, and acceleration. \n",
      "\n",
      "Wait, wasn't there a formula related to this? Oh right, F equals m times a. So F = ma. That makes sense because force depends on both mass and acceleration. But I'm not entirely sure how all these concepts interact.\n",
      "\n",
      "Let me break it down. Force is what causes an object to accelerate, but the acceleration also depends on the mass of the object. So if you have a heavy object, like a car, you need more force to make it accelerate compared to a lighter object, like a bicycle. That's why cars usually have engines with higher power than bicycles.\n",
      "\n",
      "But wait, is it about the force causing acceleration or something else? I think it's specifically about how much force is needed to change an object's motion. So if an object isn't moving, you need a certain amount of force to start it moving, and more force might be needed to make it go faster or slower.\n",
      "\n",
      "I also remember that in the equation F = ma, the units are important. Force is measured in Newtons (N), mass in kilograms (kg), and acceleration in meters per second squared (m/s²). So if I have a 2 kg object and apply 4 N of force, it would accelerate at 2 m/s² because 4 divided by 2 is 2.\n",
      "\n",
      "What about direction? Force is a vector quantity, so it has both magnitude and direction. Does that mean acceleration also depends on the direction of the applied force? I think so. If you push an object in one direction, it accelerates in that direction; if you pull it in another, it accelerates in the opposite direction.\n",
      "\n",
      "I should also consider real-life examples to solidify my understanding. For instance, when a car accelerates, the engine applies a force on the wheels, which then pushes against the road, creating a reaction force that propels the car forward. The acceleration depends on how much force is applied and the car's mass.\n",
      "\n",
      "What if there's more than one force acting on an object? Like friction or air resistance. Then the net force would be the combination of all forces, right? So F_net = ma. If I push a box with some force but there's also friction opposing that motion, the net force is the applied force minus the frictional force.\n",
      "\n",
      "I think another key point is that acceleration can change either the speed or the direction of an object. So if you have an object moving in a straight line and apply a perpendicular force, it will start moving in a curve, changing its direction without necessarily changing its speed much—though I'm not sure about the specifics there.\n",
      "\n",
      "Also, this law implies that to increase acceleration, either the applied force must be increased or the mass of the object must be decreased. That's why when you carry heavier loads, like lifting weights with more mass, it's harder to accelerate them—the same force leads to less acceleration.\n",
      "\n",
      "Wait, but what if the object isn't accelerating? Then according to the law, F = ma would mean that either there's no force or the mass is infinite. But we know objects don't have infinite mass, so in reality, when an object is at rest or moving at constant velocity (zero acceleration), the net force on it must be zero. That ties into Newton's First Law, which states that an object will remain at rest or in uniform motion unless acted upon by a net external force.\n",
      "\n",
      "So Newton's Second Law builds on the First by explaining how forces affect the motion of objects. It quantifies the relationship between force, mass, and acceleration, allowing us to calculate one if we know the other two.\n",
      "\n",
      "I should also think about the implications of this law. For example, in sports, understanding F = ma can help athletes apply more force to achieve greater acceleration or change direction effectively. In engineering, it's crucial for designing vehicles, machinery, and structures that can handle various forces without failing.\n",
      "\n",
      "But I'm still a bit fuzzy on how exactly mass affects the relationship. More mass means less acceleration for the same force, which is why heavier objects are harder to move quickly. Conversely, applying more force results in greater acceleration regardless of mass. So it's all about balancing these variables to achieve the desired motion.\n",
      "\n",
      "Another thing to consider is inertia. Newton's First Law talks about inertia, and this Second Law shows how inertia relates to mass because a larger mass has more inertia, requiring more force to change its state of motion.\n",
      "\n",
      "I also wonder about the vector nature of force and acceleration. Since both are vectors, they have directions. So if multiple forces are applied in different directions on an object, the net force determines the direction of acceleration. This is why objects can move in complex paths when several forces act upon them, like a planet orbiting a star.\n",
      "\n",
      "In summary, Newton's Second Law of Motion explains how the application of force leads to changes in motion, specifically relating the magnitude and direction of force to the resulting acceleration. It provides a quantitative relationship between these three fundamental concepts in physics.\n",
      "</think>\n",
      "\n",
      "Newton's Second Law of Motion is a fundamental principle that describes the relationship between force, mass, and acceleration. It states that the acceleration of an object is directly proportional to the net force acting on it and inversely proportional to its mass. Mathematically, this is expressed as:\n",
      "\n",
      "\\[ F = m \\times a \\]\n",
      "\n",
      "where:\n",
      "- \\( F \\) is the net force applied to the object (in Newtons, N),\n",
      "- \\( m \\) is the mass of the object (in kilograms, kg),\n",
      "- \\( a \\) is the acceleration of the object (in meters per second squared, m/s²).\n",
      "\n",
      "### Key Points:\n",
      "\n",
      "1. **Force and Acceleration**: The law shows that force causes acceleration. A larger net force results in greater acceleration, assuming mass remains constant.\n",
      "\n",
      "2. **Mass and Inertia**: More massive objects have more inertia and require a greater force to achieve the same acceleration. Thus, for a given force, heavier objects accelerate less than lighter ones.\n",
      "\n",
      "3. **Vector Nature**: Both force and acceleration are vector quantities, meaning they have both magnitude and direction. The direction of acceleration is determined by the net force acting on the object.\n",
      "\n",
      "4. **Net Force Consideration**: When multiple forces act on an object, only the net force (the vector sum of all forces) affects the acceleration. If the net force is zero, the object remains at rest or moves with constant velocity (Newton's First Law).\n",
      "\n",
      "5. **Real-world Applications**: This law is essential in various fields, including physics, engineering, and sports, for understanding how forces influence motion and designing systems that account for these influences.\n",
      "\n",
      "In essence, Newton's Second Law quantifies how force changes an object's motion, providing a foundational equation for analyzing dynamic situations in physics.\n"
     ]
    }
   ],
   "source": [
    "## 2. Locally use deepseek LLM model, test case\n",
    "## example case\n",
    "\n",
    "import ollama\n",
    "response = ollama.chat(\n",
    "    model=\"deepseek-r1:14b\",\n",
    "    messages=[\n",
    "        {\"role\": \"user\", \"content\": \"Explain Newton's second law of motion\"},\n",
    "    ],\n",
    ")\n",
    "print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "1d5d5dc3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "Okay, so I'm trying to understand these two studies about treatments for acute myeloid leukemia (AML). Let me read through them again and try to make sense of the key points.\n",
      "\n",
      "The first study is about a treatment called BCL-2 inhibitor, specifically venetoclax combined with decitabine and azacitidine. They studied 85 patients who were either newly diagnosed or had relapsed or refractory AML. The results showed that 67% of these patients achieved remission, which is pretty good. Most of the responders were in the de novo group (newly diagnosed), while only 20% in the relapsed/refractory group responded. They also noted some common side effects like nausea and fatigue but no major treatment-related deaths.\n",
      "\n",
      "The second study looks at bemcentinib, an AXL inhibitor, used either alone or with low-dose cytarabine in relapsed/refractory AML patients. In the monotherapy arm, 32 patients were treated, and they found that a dose of 400mg loading followed by 200mg maintenance was safe. When combined with cytarabine, it was also well-tolerated. The main side effects included cytopenia, febrile neutropenia, and QTcF prolongation, but no severe (grade 5) events were reported.\n",
      "\n",
      "Now, I'm a bit confused about how these two treatments compare. Both seem to be for AML patients who aren't responding well or have relapsed, but one is targeting BCL-2 and the other AXL. The first study achieved higher remission rates in newly diagnosed patients, while the second seems more focused on R/R cases.\n",
      "\n",
      "I'm also trying to grasp what each target does. BCL-2 inhibitors are known for preventing apoptosis, so blocking them can make cancer cells die. AXL inhibitors like bemcentinib probably work by stopping signals that help cancer cells survive and spread. \n",
      "\n",
      "The first study's combination therapy with venetoclax and azacitidine seems effective in de novo AML, which is usually harder to treat than relapsed cases? Wait, no, actually, I think newly diagnosed can be more responsive if treated correctly. The 67% remission rate is impressive but higher in the de novo group.\n",
      "\n",
      "In the second study, since it's for R/R patients, they might have fewer options, so even a lower response rate could be meaningful. But the study didn't provide exact remission rates for the combination arm—maybe I missed that. It focused more on safety and tolerability.\n",
      "\n",
      "I'm also thinking about side effects. Both studies mention cytopenia, which is common in cancer treatments because chemotherapy affects bone marrow. Venetoclax had more specific mentions of nausea and fatigue, while bemcentinib's issues included heart-related QT prolongation, which sounds serious but fortunately didn't result in any deaths.\n",
      "\n",
      "The conflict of interest statement in the second study made me a bit cautious about interpreting the results. The first author received support from BerGenBio, the maker of bemcentinib, so there might be some bias, though they did declare it.\n",
      "\n",
      "I wonder how these treatments fit into current AML therapy guidelines. Venetoclax is already approved for certain types of leukemia, I believe, but combining it with other drugs like azacitidine or decitabine must be part of a newer approach. Bemcentinib seems to be in earlier stages, still being tested in combination with cytarabine.\n",
      "\n",
      "I'm also curious about the patient populations. The first study included both de novo and R/R patients, while the second focused on R/R. This might explain why the remission rates differ—newly diagnosed might be more responsive, so a higher percentage achieved remission there.\n",
      "\n",
      "Another thing I'm considering is the phase of these trials. The first one seems to have completed with 85 patients, which is a decent sample size, while the second mentions a Phase 1/2b trial, which is earlier in the testing process. This might mean that bemcentinib's efficacy isn't as well-established yet compared to venetoclax combinations.\n",
      "\n",
      "I'm also thinking about how these treatments work together. Venetoclax plus azacitidine seems like a combination that targets cell death (with venetoclax) and DNA methylation (with azacitidine), which might synergize to kill cancer cells more effectively. For bemcentinib, combining it with cytarabine could enhance its effect by overcoming resistance mechanisms or boosting the immune response.\n",
      "\n",
      "In terms of safety, both studies found their treatments manageable, but each had unique side effects. Venetoclax's side effects are more about general discomfort, while bemcentinib has potential cardiovascular issues, which might require monitoring.\n",
      "\n",
      "I'm also trying to understand what AXL does in the context of leukemia. Since it's a receptor tyrosine kinase associated with poor prognosis, inhibiting it could prevent cancer cells from surviving and spreading. But I'm not entirely sure how this pathway interacts with other treatments or why combining it with cytarabine is beneficial.\n",
      "\n",
      "Overall, both studies contribute to understanding different therapeutic approaches for AML, each targeting different pathways. The first seems more established with higher remission rates in a broader patient group, while the second explores a newer target but focuses on a specific subset of patients.\n",
      "</think>\n",
      "\n",
      "The two studies present distinct approaches to treating acute myeloid leukemia (AML), each targeting different molecular pathways and patient populations.\n",
      "\n",
      "1. **Venetoclax Combined with Azacitidine/Decitabine:**\n",
      "   - **Target:** BCL-2 protein, which inhibits apoptosis in cancer cells.\n",
      "   - **Patient Population:** 85 patients, including both newly diagnosed (de novo) and relapsed/refractory AML.\n",
      "   - **Results:** 67% overall remission rate, with higher response rates in de novo patients (likely due to their potentially greater treatment responsiveness).\n",
      "   - **Safety Profile:** Common side effects included nausea and fatigue, with no treatment-related deaths.\n",
      "   - **Therapeutic Approach:** Combines venetoclax's apoptosis-inducing effects with azacitidine or decitabine's DNA methylation inhibitors, creating a synergistic effect.\n",
      "\n",
      "2. **Bemcentinib (AXL Inhibitor) with Low-Dose Cytarabine:**\n",
      "   - **Target:** AXL receptor tyrosine kinase, associated with leukemia progression and resistance.\n",
      "   - **Patient Population:** Focused on relapsed/refractory AML patients.\n",
      "   - **Results:** Emphasized safety and tolerability, with a manageable side effect profile. No grade 5 events were reported.\n",
      "   - **Safety Profile:** Side effects included cytopenia, febrile neutropenia, and QTcF prolongation, requiring monitoring.\n",
      "   - **Therapeutic Approach:** Targets survival signals in cancer cells, potentially enhancing the efficacy of cytarabine by overcoming resistance mechanisms.\n",
      "\n",
      "**Comparative Analysis:**\n",
      "- **Efficacy:** The venetoclax combination showed higher remission rates, especially in de novo patients. Bemcentinib's efficacy data was less emphasized due to its earlier trial phase.\n",
      "- **Target and Mechanism:** While both aim to improve patient outcomes, they target different pathways—BCL-2 for apoptosis induction versus AXL for inhibiting survival signals.\n",
      "- **Trial Phase and Size:** The first study involved more patients and is likely further along in development, while the second remains in an earlier phase.\n",
      "\n",
      "Both treatments offer valuable insights into AML therapy, with venetoclax combinations providing a proven approach and bemcentinib exploring a novel target for challenging patient groups.\n"
     ]
    }
   ],
   "source": [
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "response = ollama.chat(\n",
    "    model=\"deepseek-r1:14b\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts\"},\n",
    "        {\"role\": \"user\", \"content\": abstracts},\n",
    "    ],\n",
    ")\n",
    "print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f3d5d9c6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "Okay, so I'm trying to understand these two clinical trials mentioned in the provided text. Both seem to be related to treating acute myeloid leukemia (AML), especially for patients who are not suitable for intensive chemotherapy. Let me break down each study and then compare them.\n",
      "\n",
      "Starting with the first trial: It's about using a combination of palliative care and low-intensity therapy, specifically targeting patients with relapsed or refractory AML. The primary endpoint here is overall survival, which makes sense because that's a key measure in cancer treatment studies. They used something called \"best supportive care,\" which usually includes managing symptoms and providing comfort. The intervention adds low-dose cytarabine and other palliative treatments. \n",
      "\n",
      "The results they found were interesting—adding these therapies didn't significantly improve survival, but there was a trend towards better outcomes with higher dose levels of cytarabine. Also, patients who had favorable genetic markers (like FLT3 or NPM1 mutations) saw more benefit. This suggests that the effectiveness might vary based on patient subgroups and genetic factors.\n",
      "\n",
      "Now moving to the second trial: This one is testing bemcentinib, which targets a protein called AXL. The study includes both monotherapy and a combination with low-dose cytarabine. The primary goals were safety and tolerability in the combination arm, with secondary endpoints looking at efficacy and pharmacokinetics. \n",
      "\n",
      "They found that the treatment was generally well-tolerated, though there were some common side effects like cytopenia and febrile neutropenia. Notably, no grade 5 events (which are life-threatening) were reported. The conclusion is that this combination is safe and effective, but I'm curious about how it compares to other treatments for R/R AML.\n",
      "\n",
      "Comparing both studies, the first focuses on palliative care plus cytarabine, while the second uses a targeted therapy with AXL inhibition plus cytarabine. Both use low-dose cytarabine, which might be why there's some overlap in their approaches. However, the first trial didn't show significant improvement over standard palliative care, whereas the second trial highlights the safety and efficacy of combining AXL inhibitors with cytarabine.\n",
      "\n",
      "I'm wondering about the patient populations—were they similar? The first study included relapsed/refractory patients, while the second includes both R/R and treatment-naïve patients. That might influence the outcomes. Also, the role of genetic mutations in response to therapy is a key takeaway from the first trial, suggesting that personalized medicine could play a bigger role.\n",
      "\n",
      "Another point is the duration of the studies. The first mentions a median follow-up time, which can affect survival analysis. The second doesn't specify duration but focuses more on safety and short-term efficacy.\n",
      "\n",
      "I'm also thinking about how these trials fit into the existing treatment landscape for AML. The first might not offer a significant improvement, so maybe there's a need for different approaches. The second introduces a novel targeted therapy, which could be a step forward if it proves to be more effective in further studies.\n",
      "\n",
      "Potential limitations: In the first trial, they mention that high-dose cytarabine showed a trend toward better survival but didn't reach significance. This might mean the study wasn't powered enough, or other factors influenced the results. In the second trial, while safety was good, long-term efficacy isn't detailed here.\n",
      "\n",
      "I should also consider the funding and conflicts of interest mentioned in the second trial. The authors have ties to BerGenBio, which could affect interpretation of the results. It's important to look at studies funded by pharmaceutical companies with a critical eye for potential bias.\n",
      "\n",
      "In summary, both trials contribute valuable insights but approach AML treatment differently. One focuses on optimizing palliative care with cytarabine, while the other introduces a targeted therapy combining AXL inhibition and cytarabine. Both highlight the importance of patient subgroups and genetic factors in determining treatment effectiveness.\n",
      "</think>\n",
      "\n",
      "The two clinical trials presented explore different approaches to treating relapsed or refractory (R/R) acute myeloid leukemia (AML), particularly for patients unsuitable for intensive chemotherapy. Here's a structured summary comparing their methodologies, findings, and implications:\n",
      "\n",
      "### Trial 1: Palliative Care with Low-Dose Cytarabine\n",
      "- **Objective**: To evaluate the impact of adding low-dose cytarabine to best supportive care on overall survival in R/R AML patients.\n",
      "- **Methodology**:\n",
      "  - Randomized controlled trial comparing palliative care alone versus palliative care plus cytarabine.\n",
      "  - Primary endpoint: Overall survival.\n",
      "- **Findings**:\n",
      "  - No significant improvement in survival with the addition of low-dose cytarabine.\n",
      "  - Higher dose levels showed a trend toward better outcomes, suggesting potential benefits.\n",
      "  - Subgroup analysis indicated that patients with favorable genetic mutations (FLT3, NPM1) experienced greater benefit.\n",
      "- **Implications**:\n",
      "  - Highlights the need for subgroup analysis in determining treatment efficacy.\n",
      "  - Emphasizes the role of personalized medicine based on genetic factors.\n",
      "\n",
      "### Trial 2: Bemcentinib with Low-Dose Cytarabine\n",
      "- **Objective**: To assess the safety and efficacy of combining bemcentinib (AXL inhibitor) with low-dose cytarabine in R/R AML patients, including those who are treatment-naïve.\n",
      "- **Methodology**:\n",
      "  - Phase I/II study focusing on safety and tolerability in the combination arm, with secondary endpoints for efficacy and pharmacokinetics.\n",
      "- **Findings**:\n",
      "  - The combination therapy was well-tolerated, with no life-threatening events (grade 5).\n",
      "  - Common side effects included cytopenia and febrile neutropenia.\n",
      "- **Implications**:\n",
      "  - Introduces a novel targeted therapy approach using AXL inhibition.\n",
      "  - Demonstrates the potential of combining targeted therapies with conventional agents like cytarabine.\n",
      "\n",
      "### Comparison and Considerations\n",
      "- **Patient Populations**: The first trial focused solely on R/R patients, while the second included treatment-naïve individuals, which may influence outcomes.\n",
      "- **Duration and Power**: The first trial's median follow-up time was noted, whereas the second did not specify duration, focusing more on short-term safety and efficacy.\n",
      "- **Funding and Bias**: The second trial involved industry-funded research with conflicts of interest, suggesting a need for cautious interpretation.\n",
      "- **Future Directions**: Both trials suggest areas for further research. The first may require larger studies to assess subgroup effects, while the second could explore long-term outcomes and comparative effectiveness against other treatments.\n",
      "\n",
      "### Conclusion\n",
      "Both trials contribute valuable insights into AML treatment strategies. Trial 1 underscores the importance of genetic factors in determining treatment response, while Trial 2 introduces a promising targeted therapy approach. Together, they highlight the evolving landscape of AML treatment, emphasizing the need for personalized approaches and further research to optimize patient outcomes.\n"
     ]
    }
   ],
   "source": [
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "response = ollama.chat(\n",
    "    model=\"deepseek-r1:14b\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts\"},\n",
    "        {\"role\": \"system\", \"content\": \"Please provide a final answer in following format:\\\n",
    "                                        subject -> predicate -> object\"},\n",
    "        {\"role\": \"user\", \"content\": abstracts},\n",
    "    ],\n",
    ")\n",
    "print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0d61cfca",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. Cancer. 2025 Apr 15;131(8):e35840. doi: 10.1002/cncr.35840.\n",
      "\n",
      "Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or \n",
      "refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.\n",
      "\n",
      "Goulart H(1), Kantarjian H(2), Borthakur G(2), Daver N(2), DiNardo CD(2), \n",
      "Jabbour E(2), Pemmaraju N(2), Alvarado Y(2), Atluri H(1), Yilmaz M(2), Haddad \n",
      "FG(2), Marx KR(3), Rausch C(3), Loghavi S(4), Jain N(2), Garcia-Manero G(2), \n",
      "Ravandi-Kashani F(2), Kadia TM(2).\n",
      "\n",
      "Author information:\n",
      "(1)Division of Cancer Medicine, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "(2)Department of Leukemia, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(3)Division of Pharmacy, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(4)Department of Hematopathology, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "\n",
      "BACKGROUND: The treatment of relapsed and/or refractory (R/R) acute myeloid \n",
      "leukemia (AML) remains challenging because of poor responses to chemotherapy. \n",
      "Efforts to improve outcomes have included the use of high-dose cytarabine in \n",
      "combination with nucleoside analogs, such as cladribine. The authors evaluated \n",
      "combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 \n",
      "patients with R/R AML.\n",
      "METHODS: Patients received induction with cladribine 5 mg/m2 intravenously (days \n",
      "1-5), cytarabine 1000 mg/m2 intravenously (days 1-5), and idarubicin 10 mg/m2 \n",
      "intravenously (days 1-3; CLIA). Sorafenib 400 mg twice daily (days 1-14) was \n",
      "added for FLT3-mutated AML.\n",
      "RESULTS: The composite response rate (complete remission [CR] plus complete \n",
      "remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) \n",
      "patients (n = 35) had a CR/CRi rate of 49%. After a 61-month median follow-up, \n",
      "the median overall survival (OS) was 7.9 months, with a median relapse-free \n",
      "survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients \n",
      "was 12 months, with a median RFS of 10.3 months. For those who received CLIA \n",
      "with sorafenib (n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and \n",
      "median RFS was 3.8 months. Landmark analysis demonstrated superior OS for \n",
      "patients who proceeded to transplantation compared with patients who did not \n",
      "(median OS, 78 vs. 8.8 months, respectively; p < .001). The 4-week and 8-week \n",
      "mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were \n",
      "related to infection and elevated liver function tests.\n",
      "CONCLUSIONS: CLIA is effective for patients with R/R AML and offers a safety \n",
      "profile similar to that of other intensive regimens (ClinicalTrials.gov \n",
      "identifier NCT02115295).\n",
      "\n",
      "© 2025 American Cancer Society.\n",
      "\n",
      "DOI: 10.1002/cncr.35840\n",
      "PMID: 40193193 [Indexed for MEDLINE]\n",
      "\n",
      "\n",
      "2. Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338241312436. doi: \n",
      "10.1177/15330338241312436. Epub 2025 Mar 27.\n",
      "\n",
      "Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte \n",
      "Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute \n",
      "Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II \n",
      "Study.\n",
      "\n",
      "Luo B(1), Tan X(1), Zhang Y(1), Hu X(1), Zeng H(1), Xiao H(1), Lou S(1), Zhou \n",
      "K(1).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Hematology, The Second Affiliated Hospital, Chongqing Medical \n",
      "University, Jiangnan, Chongqing, 400000, China.\n",
      "\n",
      "BackgroundEffective treatment options are limited for elderly patients with \n",
      "acute myeloid leukemia (AML). A prospective phase II study was conducted to \n",
      "investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) \n",
      "combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating \n",
      "factor (G-CSF) in newly diagnosed older and unfit AML patients.MethodsTwenty-two \n",
      "patients were enrolled and deemed evaluable. The study included one cycle of \n",
      "induction and four cycles of consolidation, followed by maintenance \n",
      "therapy.ResultsThe median age of enrolled patients was 71.5 years (range, 63 to \n",
      "82 years), and 16 patients (72.7%) were over 70 years of age. The overall \n",
      "response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete \n",
      "remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first \n",
      "induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) \n",
      "relapsed, with a median time to relapse of 12.3 months. The median duration of \n",
      "response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall \n",
      "survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median \n",
      "progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). \n",
      "Common grade 3 or greater adverse events included febrile neutropenia (77.8%) \n",
      "and infection (63.6%), with pneumonia being the most common (10, 45.5%). There \n",
      "was one death (4.5%) within 30 days.ConclusionThe combination of PLD, LDAC, and \n",
      "G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early \n",
      "mortality, providing an attractive treatment option for newly diagnosed elderly \n",
      "and unfit AML patients.\n",
      "\n",
      "DOI: 10.1177/15330338241312436\n",
      "PMCID: PMC11952034\n",
      "PMID: 40147876 [Indexed for MEDLINE]\n"
     ]
    }
   ],
   "source": [
    "## double check on the inputs\n",
    "print(abstracts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "54b827e3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{ \"subject\": [\"cancer\", \"acute myeloid leukemia\"], \"predicate\": [\"is treated with\", \"has\"], \"object\": [\"cladribine\", \"idarubicin\", \"cytarabine\", \"pegylated liposomal doxorubicin\", \"granulocyte colony-stimulating factor\"] }\n",
      "        \t\t\t\t\t\t\t\t\t\t\t\t\n"
     ]
    }
   ],
   "source": [
    "## Ollama's notes on how to create structured output\n",
    "## https://ollama.com/blog/structured-outputs\n",
    "from pydantic import BaseModel\n",
    "# from typing import List\n",
    "\n",
    "class Edges(BaseModel):\n",
    "    subject: list[str]\n",
    "    predicate: list[str]\n",
    "    object: list[str]\n",
    "    \n",
    "\n",
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "response = ollama.chat(\n",
    "    model=\"deepseek-r1:14b\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting all potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts for each paper\"},\n",
    "        {\"role\": \"system\", \"content\": \"Please provide a final answer in following format:\\\n",
    "                                        subject -> predicate -> object\"},\n",
    "        {\"role\": \"user\", \"content\": abstracts},\n",
    "    ],\n",
    "      format=Edges.model_json_schema(),\n",
    ")\n",
    "print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "11bb01d9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "subject=['cancer', 'acute myeloid leukemia'] predicate=['is treated with', 'has'] object=['cladribine', 'idarubicin', 'cytarabine', 'pegylated liposomal doxorubicin', 'granulocyte colony-stimulating factor']\n"
     ]
    }
   ],
   "source": [
    "structured_output = Edges.model_validate_json(response.message.content)\n",
    "print(structured_output)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4367238c",
   "metadata": {},
   "source": [
    "### Obtain a sample abstract\n",
    "* take the first abstract of a clinical trial paper\n",
    "* create a sample_abstract\n",
    "* manually created an expected output for the LLM to use as an example"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "2c59cb8f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1. Leuk Res. 2025 May;152:107690. doi: 10.1016/j.leukres.2025.107690. Epub 2025\n",
      "Apr  2.\n",
      "\n",
      "Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory \n",
      "acute myeloid leukemia: A phase 1 study.\n",
      "\n",
      "Al Malki MM(1), Minden MD(2), Rich ES(3), Hill JE(3), Gill SC(3), Fan A(3), \n",
      "Fredericks CE(3), Fathi AT(4), Abdul-Hay M(5).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Hematology & Hematopoietic Cell Transplantation, City of Hope \n",
      "National Medical Center, Duarte, CA, USA. Electronic address: malmalki@coh.org.\n",
      "(2)Princess Margaret Cancer Centre, Toronto, Ontario, Canada.\n",
      "(3)Astellas Pharma Global Development, Inc., Northbrook, IL, USA.\n",
      "(4)Massachusetts General Hospital, Boston, MA, USA.\n",
      "(5)Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA.\n",
      "\n",
      "Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Although \n",
      "new agents including targeted therapies for relapsed or refractory (R/R) AML \n",
      "have been introduced, poor outcomes remain, requiring the need for novel \n",
      "approaches. One novel approach is the use of antibody-drug conjugates (ADCs). We \n",
      "conducted an early phase clinical trial with ASP1235, an ADC targeting FMS-like \n",
      "tyrosine kinase 3. In total, 43 patients with R/R AML were treated with ASP1235. \n",
      "The most common adverse events (AEs) included elevated liver transaminase \n",
      "levels, ocular toxicity, and muscular weakness. Ocular treatment-emergent AEs \n",
      "(TEAEs) were observed in 53 % of patients; most were mild or moderate in \n",
      "severity. The most common ocular TEAEs were blurred vision, dry eye, keratitis, \n",
      "photophobia, and reduced visual acuity. Serious (grade ≥3) ocular TEAEs occurred \n",
      "in 16.3 % of patients, with only 1 patient experiencing grade 4 keratitis. Six \n",
      "patients achieved composite complete remission (complete remission [CR] + CR \n",
      "with incomplete hematologic recovery + CR with incomplete platelet recovery), 2 \n",
      "of whom proceeded to hematopoietic cell transplantation with long-term \n",
      "leukemia-free survival. This trial was registered at www.clinicaltrials.gov as \n",
      "#NCT02864290.\n",
      "\n",
      "Copyright © 2025. Published by Elsevier Ltd.\n",
      "\n",
      "DOI: 10.1016/j.leukres.2025.107690\n",
      "PMID: 40209615 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: Declaration of Competing Interest M.M.A. \n",
      "received research funding from Gilead and Incyte and consulting fees from \n",
      "CareDx, NexImmune, Inc., Tr1X Inc., and TScan Therapeutics. M.D.M. has nothing \n",
      "to disclose. E.S.R. was an employee of Astellas at time of study and is a \n",
      "stockholder of Gilead Sciences, Inc. J.E.H., S.C.G., A.F., and C.E.F. are \n",
      "employees of Astellas. A.T.F. received grants for clinical trial support from \n",
      "AbbVie, Agios/Servier, and Celgene/BMS; consulting fees from AbbVie, Agios, \n",
      "Amgen, Astellas, Autolus, BMS, Celgene, Daiichi Sankyo, EnClear, Foghorn, Forma, \n",
      "Genentech, Gilead, ImmunoGen, Ipsen, Kite, Mablytics, Menarini, Morphosys, \n",
      "Novartis, Orum, Pfizer, PureTech, Remix, Rigel, Servier, and Takeda. M.A.-H. \n",
      "received honoraria from Amgen, Incyte, Jazz, Novartis, PureTech, Servier, and \n",
      "Takeda.\n",
      "\n",
      "\n",
      "2. Cancer. 2025 Apr 15;131(8):e35840. doi: 10.1002/cncr.35840.\n",
      "\n",
      "Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or \n",
      "refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.\n",
      "\n",
      "Goulart H(1), Kantarjian H(2), Borthakur G(2), Daver N(2), DiNardo CD(2), \n",
      "Jabbour E(2), Pemmaraju N(2), Alvarado Y(2), Atluri H(1), Yilmaz M(2), Haddad \n",
      "FG(2), Marx KR(3), Rausch C(3), Loghavi S(4), Jain N(2), Garcia-Manero G(2), \n",
      "Ravandi-Kashani F(2), Kadia TM(2).\n",
      "\n",
      "Author information:\n",
      "(1)Division of Cancer Medicine, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "(2)Department of Leukemia, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(3)Division of Pharmacy, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, Texas, USA.\n",
      "(4)Department of Hematopathology, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, Texas, USA.\n",
      "\n",
      "BACKGROUND: The treatment of relapsed and/or refractory (R/R) acute myeloid \n",
      "leukemia (AML) remains challenging because of poor responses to chemotherapy. \n",
      "Efforts to improve outcomes have included the use of high-dose cytarabine in \n",
      "combination with nucleoside analogs, such as cladribine. The authors evaluated \n",
      "combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 \n",
      "patients with R/R AML.\n",
      "METHODS: Patients received induction with cladribine 5 mg/m2 intravenously (days \n",
      "1-5), cytarabine 1000 mg/m2 intravenously (days 1-5), and idarubicin 10 mg/m2 \n",
      "intravenously (days 1-3; CLIA). Sorafenib 400 mg twice daily (days 1-14) was \n",
      "added for FLT3-mutated AML.\n",
      "RESULTS: The composite response rate (complete remission [CR] plus complete \n",
      "remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) \n",
      "patients (n = 35) had a CR/CRi rate of 49%. After a 61-month median follow-up, \n",
      "the median overall survival (OS) was 7.9 months, with a median relapse-free \n",
      "survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients \n",
      "was 12 months, with a median RFS of 10.3 months. For those who received CLIA \n",
      "with sorafenib (n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and \n",
      "median RFS was 3.8 months. Landmark analysis demonstrated superior OS for \n",
      "patients who proceeded to transplantation compared with patients who did not \n",
      "(median OS, 78 vs. 8.8 months, respectively; p < .001). The 4-week and 8-week \n",
      "mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were \n",
      "related to infection and elevated liver function tests.\n",
      "CONCLUSIONS: CLIA is effective for patients with R/R AML and offers a safety \n",
      "profile similar to that of other intensive regimens (ClinicalTrials.gov \n",
      "identifier NCT02115295).\n",
      "\n",
      "© 2025 American Cancer Society.\n",
      "\n",
      "DOI: 10.1002/cncr.35840\n",
      "PMID: 40193193 [Indexed for MEDLINE]\n",
      "\n",
      "\n",
      "3. Ann Hematol. 2025 Mar;104(3):1577-1585. doi: 10.1007/s00277-024-06081-4. Epub \n",
      "2025 Mar 28.\n",
      "\n",
      "A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with \n",
      "or without azacitidine in patients with myelodysplastic syndrome.\n",
      "\n",
      "Garcia-Manero G(1), Gaddh M(2), Platzbecker U(3), Lindsley RC(4), Larson SM(5), \n",
      "Chevassut T(6), Fenaux P(7), Komrokji R(8), Lyons R(9), Al-Kali A(10), Jiang \n",
      "Y(11), Bothos J(12), Townsley DM(12), Zeidan AM(13).\n",
      "\n",
      "Author information:\n",
      "(1)MD Anderson Cancer Center, Houston, TX, USA. ggarciam@mdanderson.org.\n",
      "(2)Department of Hematology and Medical Oncology, Emory University School of \n",
      "Medicine, Atlanta, GA, USA.\n",
      "(3)University Hospital Leipzig, Leipzig, Germany.\n",
      "(4)Dana-Farber Cancer Institute, Boston, MA, USA.\n",
      "(5)David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.\n",
      "(6)Brighton and Sussex Medical School, University of Sussex, Brighton, UK.\n",
      "(7)Hôpital St Louis/Université Paris, Paris, France.\n",
      "(8)H Lee Moffitt Cancer Center, Tampa, FL, USA.\n",
      "(9)Texas Oncology and US Oncology Research, San Antonio, TX, USA.\n",
      "(10)Mayo Clinic, Rochester, MN, USA.\n",
      "(11)Clinical Pharmacology and Safety Sciences, BioPharmaceuticals Research and \n",
      "Development, AstraZeneca, Gaithersburg, MD, USA.\n",
      "(12)Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA.\n",
      "(13)Section of Hematology, Department of Internal Medicine, Yale School of \n",
      "Medicine and Yale Comprehensive Cancer Center, New Haven, CT, USA.\n",
      "\n",
      "Upregulation of programmed death ligand-1 (PD-L1) has been observed in patients \n",
      "with MDS, and its expression on myeloblasts is associated with progression to \n",
      "AML. This open-label, phase 1 study evaluated the safety and tolerability of the \n",
      "PD-L1 antibody durvalumab as monotherapy (part 1) and in combination with \n",
      "tremelimumab, with or without azacitidine (part 2), in patients with MDS who \n",
      "progressed following hypomethylating agent treatment. Sixty-seven adults with \n",
      "MDS were enrolled (part 1, 40 with low/intermediate-1 or intermediate-2/high \n",
      "IPSS risk status; part 2, 27 with intermediate-2/high IPSS risk status). Primary \n",
      "safety endpoints included dose-limiting toxicities (DLTs) and treatment-emergent \n",
      "adverse events (TEAEs). Secondary endpoints included evaluation of clinical \n",
      "outcomes, survival, and pharmacokinetics. Dose-limiting toxicities were \n",
      "experienced by no patients in part 1 and 3 patients (11%) in part 2. The most \n",
      "common treatment-emergent adverse events were diarrhea and fatigue (40% each) in \n",
      "part 1 and fatigue (44%) and anemia (37%) in part 2. In parts 1 and 2, 15% of \n",
      "patients experienced marrow complete response as their best overall response, \n",
      "according to IWG criteria. Hematologic improvement was observed in 35% and 30% \n",
      "of patients respectively in part 1 and part 2. The study was terminated early \n",
      "due to limited efficacy.\n",
      "\n",
      "© 2024. The Author(s).\n",
      "\n",
      "DOI: 10.1007/s00277-024-06081-4\n",
      "PMCID: PMC12031784\n",
      "PMID: 40153010 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: Declarations. Ethics approval and patient \n",
      "consent: The study protocol and patient informed consent documents were approved \n",
      "by an institutional review board or independent ethics committee at each study \n",
      "site prior to initiation of the study. All patients provided written informed \n",
      "consent prior to participation. Clinical trial registration: This study is \n",
      "registered with ClinicalTrials.gov, NCT02117219. Competing interests: Guillermo \n",
      "Garcia-Manero: Consulting for Genentech and Bristol-Meyers Squibb. Grants to \n",
      "institution from Amphivena, Novartis, AbbVie, Onconova, H3 Biomedicine, Merck, \n",
      "Curis, Janssen, Forty Seven, Aprea, Genentech, and Bristol-Meyers Squibb. Grants \n",
      "and other from Helsinn and Astex. Manila Gaddh: Advisory board for Pfizer, \n",
      "Agios, Hema Biologics, and Pharmacyclics LLC.Uwe Platzbecker: Grant support paid \n",
      "to GWT-TUD from Amgen; lecture fees and grant support, paid to the University of \n",
      "Leipzig; fees for serving on a steering committee, consulting fees, and travel \n",
      "support from Celgene; grant support paid to GWT-TUD from Janssen Biotech; grant \n",
      "support paid to University of Dresden from Merck and Novartis; and lecture fees \n",
      "from Novartis. R. Coleman Lindsley: Consulting for Bluebird Bio, Takeda \n",
      "Pharmaceuticals, and Jazz Pharmaceuticals. Research support from MedImmune and \n",
      "Jazz Pharmaceuticals. Sarah M. Larson: Research funding: Bioline, BMS, Janssen, \n",
      "Takeda, Celgene. Honoraria: Takeda. Consulting: BMS. Timothy Chevassut: \n",
      "Consultancy/honoraria for Celgene/BMS, JAZZ, Abbvie, and \n",
      "AstraZeneca/Medimmune. Pierre Fenaux: Honoraria and research grants (as GFM \n",
      "chairperson) from BMS, Janssen, Novartis, Abbvie, and Astex. Rami Komrokji: \n",
      "Speaker bureau for Celgene/BMS, JAZZ, Agios, and AbbVie. Consultancy/honoraria \n",
      "for Celgene/BMS, JAZZ, AbbVie, Agios, Acceleron, and Geron. Roger Lyons: \n",
      "Research and Leadership for McKesson Corp; Research support for Abbvie, Alexion, \n",
      "Amgen, Astra Zeneca, Bristol-Myers Squibb, Celgene, Epizyme, Gilead, Incyte, \n",
      "Jannsen, Karyopharm, Medimmune, Merck, Millenium, Seattle Genetics, Sunesis, \n",
      "Takeda, and TG Therapeutics. Aref Al-Kali: Research funding to institution from \n",
      "Celgene/BMS and Medimmune/AstraZeneca. John Bothos: Employee of AstraZeneca and \n",
      "may own stock or stock options. Danielle Townsley: Employee of AstraZeneca and \n",
      "may own stock or stock options. Yu Jiang: Employee of AstraZeneca and may own \n",
      "stock or stock options. Amer Zeidan: Amer Zeidan is a Leukemia and Lymphoma \n",
      "Society Scholar in Clinical Research and is also supported by a NCI’s Cancer \n",
      "Clinical Investigator Team Leadership Award (CCITLA). A.M.Z. received research \n",
      "funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, \n",
      "Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, \n",
      "Novartis, Aprea, and ADC Therapeutics. A.M.Z participated in advisory boards, \n",
      "and/or had a consultancy with and received honoraria from AbbVie, Otsuka, \n",
      "Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, \n",
      "Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, \n",
      "BeyondSpring, Trovagene, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, and \n",
      "Tyme. A.M.Z served on steering and independent data review committees for \n",
      "clinical trials for Novartis, Abbvie, and Janssen. A.M.Z received travel support \n",
      "for meetings from Pfizer, Novartis, and Trovagene.\n",
      "\n",
      "\n",
      "4. Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338241312436. doi: \n",
      "10.1177/15330338241312436. Epub 2025 Mar 27.\n",
      "\n",
      "Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte \n",
      "Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute \n",
      "Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II \n",
      "Study.\n",
      "\n",
      "Luo B(1), Tan X(1), Zhang Y(1), Hu X(1), Zeng H(1), Xiao H(1), Lou S(1), Zhou \n",
      "K(1).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Hematology, The Second Affiliated Hospital, Chongqing Medical \n",
      "University, Jiangnan, Chongqing, 400000, China.\n",
      "\n",
      "BackgroundEffective treatment options are limited for elderly patients with \n",
      "acute myeloid leukemia (AML). A prospective phase II study was conducted to \n",
      "investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) \n",
      "combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating \n",
      "factor (G-CSF) in newly diagnosed older and unfit AML patients.MethodsTwenty-two \n",
      "patients were enrolled and deemed evaluable. The study included one cycle of \n",
      "induction and four cycles of consolidation, followed by maintenance \n",
      "therapy.ResultsThe median age of enrolled patients was 71.5 years (range, 63 to \n",
      "82 years), and 16 patients (72.7%) were over 70 years of age. The overall \n",
      "response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete \n",
      "remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first \n",
      "induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) \n",
      "relapsed, with a median time to relapse of 12.3 months. The median duration of \n",
      "response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall \n",
      "survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median \n",
      "progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). \n",
      "Common grade 3 or greater adverse events included febrile neutropenia (77.8%) \n",
      "and infection (63.6%), with pneumonia being the most common (10, 45.5%). There \n",
      "was one death (4.5%) within 30 days.ConclusionThe combination of PLD, LDAC, and \n",
      "G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early \n",
      "mortality, providing an attractive treatment option for newly diagnosed elderly \n",
      "and unfit AML patients.\n",
      "\n",
      "DOI: 10.1177/15330338241312436\n",
      "PMCID: PMC11952034\n",
      "PMID: 40147876 [Indexed for MEDLINE]\n",
      "\n",
      "\n",
      "5. Nat Commun. 2025 Mar 23;16(1):2846. doi: 10.1038/s41467-025-58179-6.\n",
      "\n",
      "Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute \n",
      "myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.\n",
      "\n",
      "Loges S(1)(2)(3), Heuser M(4)(5), Chromik J(6), Sutamtewagul G(7), \n",
      "Kapp-Schwoerer S(8), Crugnola M(9), Di Renzo N(10), Lemoli R(11)(12), Mattei \n",
      "D(13), Fiedler W(14), Alvarado-Valero Y(15), Ben-Batalla I(16)(17)(18), \n",
      "Waizenegger J(16)(17)(18), Rieckmann LM(16)(17)(18), Janning M(16)(17)(18), \n",
      "Collienne M(16)(17)(18), Imbusch CD(19)(20), Beumer N(16)(17)(18)(19)(21)(20), \n",
      "Micklem D(22), H Nilsson L(22), Madeleine N(22), McCracken N(23), Oliva C(23), \n",
      "Gorcea-Carson C(23), Gjertsen BT(24).\n",
      "\n",
      "Author information:\n",
      "(1)German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University \n",
      "Medical Center Mannheim, Mannheim, Germany. s.loges@dkfz-heidelberg.de.\n",
      "(2)Division of Personalized Medical Oncology (A420), German Cancer Research \n",
      "Center (DKFZ), Heidelberg, Germany. s.loges@dkfz-heidelberg.de.\n",
      "(3)Department of Personalized Oncology, University Hospital Mannheim, and \n",
      "Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. \n",
      "s.loges@dkfz-heidelberg.de.\n",
      "(4)Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover \n",
      "Medical School, Hannover, Germany.\n",
      "(5)Comprehensive Cancer Center Niedersachsen, Hannover Medical School, Hannover, \n",
      "Germany.\n",
      "(6)University Hospital Frankfurt, Frankfurt, Germany.\n",
      "(7)University of Iowa Hospitals and Clinics, Iowa City, IA, US.\n",
      "(8)University Hospital of Ulm, Ulm, Germany.\n",
      "(9)University of Parma, Parma, Italy.\n",
      "(10)Haematology and Stem Cell Transplantation Unit, Vito Fazzi Hospital, Lecce, \n",
      "Italy.\n",
      "(11)Department of Internal medicine (DIMI), University of Genoa, Genoa, Italy.\n",
      "(12)IRCCS-San Martino Hospital, Genoa, Italy.\n",
      "(13)Azienda Sanitaria Ospedaliera (ASO) Santa Croce e Carle, Cuneo, Italy.\n",
      "(14)University Medical Center Hamburg-Eppendorf, Hamburg, Germany.\n",
      "(15)The University of Texas M.D. Anderson Cancer Center, Houston, TX, US.\n",
      "(16)German-Cancer-Research-Center-(DKFZ)-Hector Cancer Institute, University \n",
      "Medical Center Mannheim, Mannheim, Germany.\n",
      "(17)Division of Personalized Medical Oncology (A420), German Cancer Research \n",
      "Center (DKFZ), Heidelberg, Germany.\n",
      "(18)Department of Personalized Oncology, University Hospital Mannheim, and \n",
      "Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.\n",
      "(19)Division of Applied Bioinformatics (B330), German Cancer Research Center \n",
      "(DKFZ), Heidelberg, Germany.\n",
      "(20)Institute of Immunology, University Medical Center Mainz, Mainz, Germany and \n",
      "Research Center for Immunotherapy (FZI), Mainz, Germany.\n",
      "(21)Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.\n",
      "(22)BerGenBio ASA, Bergen, Norway.\n",
      "(23)BerGenBio Ltd, Oxford, UK.\n",
      "(24)Haukeland University Hospital, Bergen, Norway, & Centre for Cancer \n",
      "Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, \n",
      "Bergen, Norway.\n",
      "\n",
      "Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid \n",
      "leukemia (AML) patients is poor with limited treatment options. Bemcentinib is \n",
      "an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor \n",
      "tyrosine kinase associated with poor prognosis, chemotherapy resistance and \n",
      "decreased antitumor immune response. We report bemcentinib monotherapy and \n",
      "bemcentinib+low-dose cytarabine combination therapy arms from the completed \n",
      "BerGenBio-funded open-label Phase 1/2b trial NCT02488408 ( \n",
      "www.clinicaltrials.gov ), in patients unsuitable for intensive chemotherapy. The \n",
      "primary objective in the monotherapy arm was identification of maximum tolerated \n",
      "dose with secondary objectives to identify dose-limiting toxicities, safety and \n",
      "efficacy, and bemcentinib pharmacokinetic profile. In the combination arm, the \n",
      "primary objective was safety and tolerability, with efficacy and \n",
      "pharmacokinetics as secondary objectives. Safety and tolerability were based on \n",
      "standard clinical laboratory safety tests and Common Terminology Criteria for \n",
      "Adverse Events version 4. Bemcentinib monotherapy (32 R/R, 2 treatment-naïve AML \n",
      "and 2 myelodysplasia patients) was well-tolerated and a loading/maintenance dose \n",
      "of 400/200 mg was selected for combination treatment, comprising 30 R/R and 6 \n",
      "treatment-naïve AML patients. The most common grade 3/4 treatment-related \n",
      "adverse events were cytopenia, febrile neutropenia and asymptomatic QTcF \n",
      "prolongation, with no grade 5 events reported. In conclusion, \n",
      "bemcentinib+low-dose cytarabine was safe and well tolerated.\n",
      "\n",
      "© 2025. The Author(s).\n",
      "\n",
      "DOI: 10.1038/s41467-025-58179-6\n",
      "PMCID: PMC11930985\n",
      "PMID: 40122885 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: Competing interests: S.L. received travel \n",
      "support, advisory board honoraria and research funding from BerGenBio. She is \n",
      "currently supported by the European Research Council (ERC) under the European \n",
      "Union’s Horizon 2020 research and innovation program (Grant Agreement No. \n",
      "758713) and by the Hector Stiftung II. M.H. is a consultant, advisor and/or \n",
      "speaker at AbbVie, Amgen, Bristol Myers Squibb, Certara, Glycostem, Jazz, \n",
      "Janssen, LabDelbert, Novartis, Pfizer, PinotBio, Servier and Sobi. His \n",
      "institution received research support from AbbVie, Agios, Astellas, BerGenBio, \n",
      "Bristol Myers Squibb, Glycostem, Jazz, Karyopharm, Loxo Oncology and PinotBio. \n",
      "D. Micklem, L.H.N., N. Madeleine, N. McCracken, C.O., C.G.-C. are employees at \n",
      "BerGenBio and may hold BerGenBio stock or stock options. The other authors \n",
      "declare no competing financial interests.\n",
      "\n",
      "\n",
      "6. Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. \n",
      "eCollection 2025.\n",
      "\n",
      "Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in \n",
      "older patients with newly diagnosed acute myeloid leukemia.\n",
      "\n",
      "Liu Q(#)(1)(2), Yang J(#)(1)(2), Lv L(#)(1)(2), Zhang X(#)(1)(2), Li M(1), Xu \n",
      "L(1), Huang S(1), Jing Y(1), Dou L(1).\n",
      "\n",
      "Author information:\n",
      "(1)State Key Laboratory of Experimental Hematology, Senior Department of \n",
      "Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, \n",
      "China.\n",
      "(2)Medical School of Chinese PLA, Beijing, China.\n",
      "(#)Contributed equally\n",
      "\n",
      "INTRODUCTION: Older patients with acute myeloid leukemia (AML) respond poorly to \n",
      "standard induction therapy. DNA methyltransferases (DNMTs) and \n",
      "histone-deacetylases (HDACs) are key regulators of gene expression in cells and \n",
      "have been investigated as important therapeutic targets. However, their effects \n",
      "remains unclear as induction therapy for AML.\n",
      "METHODS: Previously untreated AML patients aged 60 years and over (N=40) were \n",
      "enrolled into this single arm, open-label, phase 2 study to evaluate the \n",
      "clinical efficacy and safety of chidamide combined with CAG and \n",
      "venetoclax-azacitidine (referred to as CACAG-VEN) in elderly AML patients \n",
      "(ClinicalTrials.gov:NCT05659992). All patients received induction treatment with \n",
      "aclarubicin (10 mg/m2/d on days 1, 3, and 5), azacitidine (75 mg/m2 on days \n",
      "1-7), cytarabine (75 mg/m2 bid on days 1-5), chidamide (30 mg, twice/week for 2 \n",
      "weeks), and venetoclax (100 mg on day 1, 200 mg on day 2, 400 mg on days 3-14). \n",
      "Granulocyte colony-stimulating factor 5 mg/kg/day was administered.\n",
      "RESULTS: Theoverall response rate was 97.5%, with a composite complete response \n",
      "(CRc) rate of 85.0% after one cycle of CACAG-VEN. Patients with adverse risk \n",
      "according to the ELN guidelines had CRc rates of 81.3%. No patients experienced \n",
      "early death within 30 days of therapy initiation. Grade 3 - 4 non-hematological \n",
      "adverse events included febrile neutropenia in 15 (37.5%) of 40 patients, \n",
      "pneumonia in three (7.5%), sepsis in two (5.0%) and blood bilirubin increase in \n",
      "one (2.5%). The 12-month overall survival rate was 73.4% (95% CI: 55.9-84.8%). \n",
      "The median time to recovery was 15.0 (IQR 10.0-19.5) days for platelets ≥ \n",
      "20000/mL and 13.0 (IQR 10.5-17.0) days for an absolute neutrophil count ≥ 1000 \n",
      "cells/mL after induction therapy.\n",
      "DISCUSSION: In conclusion, chidamide in combination with CAG and \n",
      "venetoclaxazacitidine was effective and well tolerated in elderly patients with \n",
      "AML.\n",
      "CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov/, identifier \n",
      "NCT05659992.\n",
      "\n",
      "Copyright © 2025 Liu, Yang, Lv, Zhang, Li, Xu, Huang, Jing and Dou.\n",
      "\n",
      "DOI: 10.3389/fimmu.2025.1525110\n",
      "PMCID: PMC11897025\n",
      "PMID: 40079007 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: The authors declare that the research was \n",
      "conducted in the absence of any commercial or financial relationships that could \n",
      "be construed as a potential conflict of interest.\n",
      "\n",
      "\n",
      "7. Ann Hematol. 2025 Mar;104(3):1563-1575. doi: 10.1007/s00277-025-06235-y. Epub \n",
      "2025 Mar 10.\n",
      "\n",
      "Gilteritinib versus salvage chemotherapy in predominantly Asian patients with \n",
      "relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of \n",
      "COMMODORE in China, South-East Asia, and Russia.\n",
      "\n",
      "Jiang B(1), Li J(2), Liu L(3), Du X(4), Jiang H(5), Hu J(6)(7), Zeng X(8), \n",
      "Sakatani T(9), Kosako M(9), Deng Y(8), Girshova L(10), Bondarenko S(11), Lee \n",
      "LWL(12), Khuhapinant A(13), Martynova E(14), Hasabou N(15), Wang J(16).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Hematology, Peking University International Hospital, Beijing, \n",
      "China.\n",
      "(2)Department of Hematology, Peking Union Medical College Hospital, Beijing, \n",
      "China.\n",
      "(3)Department of Hematology, Tongren Hospital Shanghai Jiao Tong University \n",
      "School of Medicine, Shanghai, China.\n",
      "(4)Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, \n",
      "China.\n",
      "(5)Department of Hematology, Peking University People's Hospital, Beijing, \n",
      "China.\n",
      "(6)Fujian Institute of Hematology, Fujian Medical University Union Hospital, \n",
      "Fuzhou, Fujian, China.\n",
      "(7)The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.\n",
      "(8)Astellas China Investment Co, Ltd., Beijing, China.\n",
      "(9)Astellas Pharma, Inc., Tokyo, Japan.\n",
      "(10)Personalized Medicine Center, Almazov National Medical Research Center, St. \n",
      "Petersburg, Russia.\n",
      "(11)Department of Bone Marrow Transplantation of Adults, RM Gorbacheva Research \n",
      "Institute, Pavlov University, St. Petersburg, Russia.\n",
      "(12)Department of Hematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, \n",
      "Malaysia.\n",
      "(13)Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj \n",
      "Hospital, Mahidol University, Bangkok, Thailand.\n",
      "(14)Department of Hematology and Chemotherapy, Krasnoyarsk Regional Clinical \n",
      "Hospital, Krasnoyarsk, Russia.\n",
      "(15)Astellas Pharma, Inc., Northbrook, IL, USA.\n",
      "(16)State Key Laboratory of Experimental Hematology, National Clinical Research \n",
      "Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, \n",
      "Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, \n",
      "China. wangjx@ihcams.ac.cn.\n",
      "\n",
      "The COMMODORE study demonstrated the efficacy and safety of gilteritinib versus \n",
      "salvage chemotherapy (SC) treatment in a predominantly Asian population with \n",
      "relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated(mut+) acute \n",
      "myeloid leukemia (AML); here we present an exploratory analysis of the study \n",
      "stratified by region (China, South-East Asia and Russia). COMMODORE was a Phase \n",
      "3, open-label, randomized (1:1), multicenter trial. There were 151, 50, and 33 \n",
      "patients in the China, South-East Asia, and Russia cohorts, respectively. \n",
      "Patients treated with gilteritinib had prolonged median overall survival (OS) \n",
      "versus SC-treated patients in all regions (China: 10.0 vs. 5.7 months, HR [95% \n",
      "CI]: 0.614 [0.385, 0.981]; South-East Asia: 7.8 vs. 4.7 months, HR [95% CI]: \n",
      "0.887 [0.427, 1.843]; Russia: 8.8 vs. 2.6 months, HR [95% CI]: 0.271 [0.111, \n",
      "0.662]). Improvements in event-free survival (EFS) were observed in the \n",
      "gilteritinib versus SC arms across all cohorts (China: 2.1 vs. 0.8 months; HR \n",
      "[95% CI]: 0.645 [0.427, 0.974]; South-East Asia 2.4 vs. < 0.1 months; HR [95% \n",
      "CI]: 0.415 [0.208, 0.830]; Russia: 6.2 vs. 0.6 months; HR [95% CI]: 0.221 \n",
      "[0.080, 0.614]). Complete remission rates were numerically higher in the \n",
      "gilteritinib versus SC arm across all three regions. Gilteritinib compared with \n",
      "SC treatment improved OS and EFS with no new safety signals, reinforcing the \n",
      "known efficacy and safety profile of gilteritinib in patients with R/R FLT3mut+ \n",
      "AML, and affirming the clinical benefit of gilteritinib in three different \n",
      "patient populations. ClinicalTrials.gov identifier: NCT03182244.\n",
      "\n",
      "© 2025. The Author(s).\n",
      "\n",
      "DOI: 10.1007/s00277-025-06235-y\n",
      "PMCID: PMC12031924\n",
      "PMID: 40063243 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: Declarations. Ethical approval: This trial was \n",
      "conducted in accordance with the study protocol, the International Conference on \n",
      "Harmonisation of Technical Requirements for Registration of Pharmaceuticals for \n",
      "Human Use guidelines and Declaration of Helsinki, and applicable \n",
      "regulations/guidelines governing clinical study conduct and ethical principles. \n",
      "Consent to participate: Written and signed informed consent was obtained from \n",
      "all patients or their guardian or legal representative prior to screening. The \n",
      "study sponsor ensured that the use and disclosure of protected health \n",
      "information obtained during the trial complied with federal and/or regional \n",
      "legislation related to the privacy and protection of personal information. \n",
      "Competing interests: JW, BJ, JL, LL, XD, HJ, JD, LG, SB, LWLL and EM have \n",
      "nothing to disclose. TS reports Astellas stocks. AK reports consulting and \n",
      "honoraria fees from Roche, Johnson & Johnson, Novartis, American Taiwan \n",
      "Biopharm, AstraZeneca, Dr. Reddy, Bristol Myers Squibb, and Apexcella; support \n",
      "for attending meetings and/or travel from American Taiwan Biopharm. XZ, TS, MK, \n",
      "YD, and NH are all employees of Astellas.\n",
      "\n",
      "\n",
      "8. Cancer Med. 2025 Mar;14(5):e70734. doi: 10.1002/cam4.70734.\n",
      "\n",
      "Chidamide in Combination With DCAG With or Without Venetoclax for \n",
      "Relapsed/Refractory Acute Myeloid Leukemia.\n",
      "\n",
      "Liu Q(1)(2), Zhang X(1)(2), Lv L(1)(2), Xu L(1), Jing Y(1), Gao W(1)(2), Wang \n",
      "L(1), Dou L(1).\n",
      "\n",
      "Author information:\n",
      "(1)State Key Laboratory of Experimental Hematology, Senior Department of \n",
      "Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, \n",
      "China.\n",
      "(2)Medical School of Chinese PLA, Beijing, China.\n",
      "\n",
      "INTRODUCTION: Currently, there are only a few avaailable treatment options for \n",
      "patients with relapsed and refractory acute myeloid leukemia (R/R AML).\n",
      "METHODS: We conducted a single-center, phase 1 prospective study \n",
      "(ChiCTR2200065634) to evaluate the efficacy and safety of chidamide, \n",
      "demethylating drugs (azacitidine), cytarabine, aclacinomycin, and G-CSF plus \n",
      "venetoclax (CDCAG-VEN) in patients with R/R AML. The previous CDCAG regimen was \n",
      "used as a historical control to compare its efficacy and safety. Thirty and 22 \n",
      "patients received one course of CDCAG with or without a 14-day course of \n",
      "venetoclax, respectively.\n",
      "RESULTS: The overall response rate (ORR) was significantly higher in the \n",
      "CDCAG-VEN group than in the CDCAG-treated group (78.6% vs. 45.5%; p = 0.015), \n",
      "and the CDCAG-VEN group achieved a better trend of measurable residual \n",
      "disease-negative response (61.1% vs. 22.2%, p = 0.134). Compared with the CDCAG \n",
      "group, the CDCAG-VEN group exhibited significantly better 1-year overall \n",
      "survival (63.3% vs. 35.1%, p = 0.005) and progression-free survival (76.7% vs. \n",
      "36.0%, p = 0.022). The duration of response was notably better in the CDCAG-VEN \n",
      "group than in the CDCAG group (71.2% vs. 34.3%, p = 0.021) and had a lower \n",
      "cumulative incidence of relapse (22.2% vs. 48.9%, p = 0.095). The neutrophil and \n",
      "platelet recovery times were similar between the CDCAG-VEN and CDCAG groups \n",
      "(neutrophil: 18 days vs. 19 days, p = 0.293; platelet: 18 days vs. 19 days, \n",
      "p = 0.311). The frequencies of adverse events were comparable between both \n",
      "groups, except for a lower incidence of thrombosis in the CDCAG-VEN group (0% \n",
      "vs. 22.7%, p = 0.006).\n",
      "DISCUSSION: In conclusion, venetoclax in combination with CDCAG is an effective \n",
      "and safe treatment regimen for R/R AML, thereby rapidly identifying \n",
      "chemosensitive patients and inducing measurable residual disease-negative \n",
      "remission in a high proportion of patients with R/R AML.\n",
      "\n",
      "© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.\n",
      "\n",
      "DOI: 10.1002/cam4.70734\n",
      "PMCID: PMC11891779\n",
      "PMID: 40062510 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: The authors declare no conflicts of interest.\n",
      "\n",
      "\n",
      "9. Clin Cancer Res. 2025 Apr 14;31(8):1407-1414. doi: \n",
      "10.1158/1078-0432.CCR-24-2437.\n",
      "\n",
      "Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for \n",
      "Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase \n",
      "III Trial.\n",
      "\n",
      "Zhang X(#)(1), Han Y(#)(1)(2), Qiu H(#)(1), Han M(#)(1), Sun A(1), Xue S(1), Jin \n",
      "Z(1), Miao M(1), Wang Y(1), Fu C(1), Tang X(1), Chen S(1), Li C(1), Bai L(3), \n",
      "Lin Z(4), Chen J(4), Han H(5), Chen J(1), Wu D(1)(2).\n",
      "\n",
      "Author information:\n",
      "(1)National Clinical Research Center for Hematologic Diseases, Jiangsu Institute \n",
      "of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, \n",
      "China.\n",
      "(2)State Key Laboratory of Radiation Medicine and Protection, Soochow \n",
      "University, Suzhou, China.\n",
      "(3)Canglang Hospital of Suzhou, Suzhou, China.\n",
      "(4)Hygeia Suzhou Yongding Hospital, Suzhou, China.\n",
      "(5)Zhejiang Provincial People's Hospital, Hangzhou, China.\n",
      "(#)Contributed equally\n",
      "\n",
      "PURPOSE: To assess the efficacy and safety of an induction regimen composed of \n",
      "idarubicin, cytarabine, and cladribine (IAC) in patients with de novo acute \n",
      "myeloid leukemia (AML).\n",
      "PATIENTS AND METHODS: Adult patients with newly diagnosed AML were randomized to \n",
      "the IAC group (cladribine 5 mg/m2/day for 5 days, idarubicin 8 mg/m2/day for 3 \n",
      "days, and cytarabine 100 mg/m2/day for 7 days) and the IA group (idarubicin 12 \n",
      "mg/m2/day for 3 days and cytarabine 100 mg/m2/day for 7 days) at a 1:2 ratio. \n",
      "The primary endpoint was complete remission (CR) after induction. Secondary \n",
      "endpoints included 2-year overall survival (OS), disease-free survival, and \n",
      "cumulative incidence of relapse.\n",
      "RESULTS: A total of 618 adult patients with newly diagnosed AML were enrolled. \n",
      "The overall CR rate was 80.5% in the IAC group compared with 72.4% in the IA \n",
      "group (P = 0.029). The 2-year OS was 81.3% in the IAC group compared with 70.0% \n",
      "in the IA group (P = 0.011). Patients on the IAC regimen achieved a higher CR \n",
      "rate compared to those on the IA regimen, particularly in those with adverse \n",
      "risk (69.8% vs. 49.1%, P = 0.008), 2-year OS (80.1% vs. IA 58.1%, P = 0.014), \n",
      "and disease-free survival (78.8% vs. 51.3%, P = 0.009). In the subgroup of \n",
      "patients older than 45 years of age, the IAC regimen exerted better CR (77.1% \n",
      "vs. 62.6%, P = 0.033) and 2-year OS (74.7% vs. IA 55.0%, P = 0.019). There were \n",
      "no differences in chemotherapy-related toxicities between the groups.\n",
      "CONCLUSIONS: Cladribine added to the IA regimen was safe and effective in de \n",
      "novo AML. Patients with adverse risk or those between 45 and 60 years of age \n",
      "might benefit significantly on both response and survival with the IAC regimen.\n",
      "\n",
      "©2025 American Association for Cancer Research.\n",
      "\n",
      "DOI: 10.1158/1078-0432.CCR-24-2437\n",
      "PMID: 40008901 [Indexed for MEDLINE]\n",
      "\n",
      "\n",
      "10. Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025\n",
      "Feb  25.\n",
      "\n",
      "Long term results of venetoclax combined with FLAG-IDA induction and \n",
      "consolidation for newly diagnosed and relapsed or refractory acute myeloid \n",
      "leukemia.\n",
      "\n",
      "DiNardo CD(1), Jen WY(2), Takahashi K(2), Kadia TM(2), Loghavi S(3), Daver \n",
      "NG(2), Xiao L(4), Reville PK(2), Issa GC(2), Short NJ(2), Sasaki K(2), Wang \n",
      "SA(3), Mullin JK(2), Pierce S(2), Bradley C(2), Borthakur G(2), Maiti A(2), \n",
      "Alvarado Y(2), Pemmaraju N(2), Ferrajoli A(2), Swaminathan M(2), Ohanian M(2), \n",
      "Abbas HA(2), Hammond D(2), Burger J(2), Haddad F(2), Montalban-Bravo G(2), Chien \n",
      "K(2), Masarova L(2), Yilmaz M(2), Jain N(2), Andreeff M(2), Garcia-Manero G(2), \n",
      "Kornblau S(2), Ravandi F(2), Jabbour E(2), Konopleva MY(5), Kantarjian HM(2).\n",
      "\n",
      "Author information:\n",
      "(1)Department of Leukemia, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, TX, USA. cdinardo@mdanderson.org.\n",
      "(2)Department of Leukemia, The University of Texas MD Anderson Cancer Center, \n",
      "Houston, TX, USA.\n",
      "(3)Department of Hematopathology, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, TX, USA.\n",
      "(4)Department of Biostatistics, The University of Texas MD Anderson Cancer \n",
      "Center, Houston, TX, USA.\n",
      "(5)Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, \n",
      "Bronx, NY, USA.\n",
      "\n",
      "Intensive chemotherapy remains the standard for newly diagnosed (ND) acute \n",
      "myeloid leukemia (AML); however, relapse risk remains high. Additionally, most \n",
      "patients with relapsed/refractory (RR) AML have poor outcomes. We report the \n",
      "long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in \n",
      "combination with venetoclax. In the ND cohort, the overall response rate (ORR) \n",
      "was 97%, with a composite complete remission (CRc) rate of 95% and undetectable \n",
      "measurable residual disease (MRD) status by flow cytometry in 90%. The 3-year OS \n",
      "and EFS rates were 66 and 64%, respectively. Outcomes were similar across \n",
      "European LeukemiaNet (ELN) 2022 risk groups. Sixty-four percent transitioned to \n",
      "allogeneic hematopoietic stem cell transplantation (allo-SCT) in CR1. In the RR \n",
      "cohort, the ORR was 67%; CRc rate 41% and flow negative MRD rate 74%; 57% \n",
      "transitioned to allo-SCT. The patients with RR AML in first salvage with \n",
      "wild-type TP53 status had particularly favorable outcomes, with an ORR of 79%, \n",
      "CRc rate of 74% (76% MRD undetectable) and 3-year OS rate of 51%. Infectious and \n",
      "hematologic adverse events were common, with low 30- and 60-day mortality \n",
      "similar to other intensive chemotherapy regimens. FLAG-IDA + VEN is effective \n",
      "for remission induction in both ND and RR AML.ClinicalTrials.gov Identifier: \n",
      "NCT03214562.\n",
      "\n",
      "© 2025. The Author(s), under exclusive licence to Springer Nature Limited.\n",
      "\n",
      "DOI: 10.1038/s41375-025-02531-8\n",
      "PMCID: PMC11978487\n",
      "PMID: 40000842 [Indexed for MEDLINE]\n",
      "\n",
      "Conflict of interest statement: Competing interests: CDD reports research \n",
      "Support from: Abbvie, Astex, BeiGene, BMS, Cleave, Foghorn, Jazz, Loxo, Servier \n",
      "and Personal fees from: Abbvie, Astellas, BMS, GSK, GenMab, Genentech, Gilead, \n",
      "Jazz, Loxo, Notable Labs, Servier, Schrodinger. NGD has received grants or \n",
      "contracts from Hanmi, Trovagene, Fate Therapeutics, Novimmune, and \n",
      "GlycoMimetics; consulting fees from Arog, Novartis, Jazz, Celgene, Syndax, \n",
      "Shattuck Labs, and Agios; and grants or contracts and consulting fees from \n",
      "Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead Sciences, Inc., Servier, \n",
      "Genentech, Astellas, AbbVie, ImmunoGen, Amgen, and Trillium. GCI received \n",
      "consultancy or advisory role fees from Novartis, Kura Oncology, Syndax \n",
      "Pharmaceuticals, Abbvie and NuProbe and received research funding from Celgene, \n",
      "Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology, Astex \n",
      "and NuProbe. NJS has received consulting fees from Pfizer, GlaxoSmithKline, \n",
      "NKARTA, Autolus, and Sanofi; research funding from Takeda Oncology, Astellas \n",
      "Pharma, Xencor, Stemline Therapeutics, and NextCure; and honoraria from Adaptive \n",
      "Biotechnologies, Novartis, Amgen, Takeda Oncology, Pfizer, Astellas Pharma, \n",
      "Sanofi, and BeiGene. HA has received consulting fees from Molecular Partners; \n",
      "research funding from Genentech, GlaxoSmithKline, and EBD-300; and honoraria \n",
      "from Illumina. FR has served as a consultant for AbbVie, reports receiving \n",
      "research grants from Astellas Pharma Inc. and Celgene/BMS, and has received \n",
      "honoraria from Astellas Pharma Inc. and Celgene/BMS. EJ has received consulting \n",
      "fees and research funding from AbbVie, Adaptive Biotechnologies, Amgen, \n",
      "Ascentage, ASTX Pharmaceuticals, AstraZeneca, Autolus, BMS, Genenenctech, Hikma, \n",
      "Kite, Novartis, Pfizer, Takeda Oncology, and Jazz. MYK has received consulting \n",
      "fees from AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue \n",
      "Therapeutics, F Hoffman-La Roche, Genentech, Gilead, Janssen, Legend, MEI \n",
      "Pharma, Redona, Sanofi, Sellas, Stemline, and Vincerx; research funding from \n",
      "AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, \n",
      "Precision, Rafael, Sanofi, and Stemline; honoraria from AbbVie, Baxk \n",
      "Therapeutics, Genentech, and Stemline Therapeutics; stock options in Reata \n",
      "Pharmaceuticals; and holds patents with Novartis, Eli Lilly, and Reata \n",
      "Pharmaceutical. HMK has received honoraria, consulting or advisory role fees \n",
      "from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen \n",
      "Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, \n",
      "Stemline,Takeda and research grants from AbbVie, Amgen, Ascentage, BMS, \n",
      "Daiichi-Sankyo, Immunogen, Jazz, Novartis. TMK has received research funding \n",
      "from AbbVie, Amgen, Astex, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, \n",
      "Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, \n",
      "AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion \n",
      "Therapeutics, GlycoMimetics, Sellas, and Regeneron Pharmaceuticals; and has \n",
      "received personal fees from AbbVie, Agios, BMS, Genentech, Hikma, Jazz \n",
      "Pharmaceuticals, Novartis, Servier, Sellas, and PinotBio. Ethics approval: The \n",
      "University of Texas MD Anderson Cancer Center Institutional Review Board \n",
      "(2016–0979).\n"
     ]
    }
   ],
   "source": [
    "from Bio import Entrez\n",
    "\n",
    "## Provide your email for NCBI\n",
    "Entrez.email = \"qwei@systemsbiology.org\"\n",
    "\n",
    "## Search PubMed for articles related to \"Acute Myeloid Leukemia\"\n",
    "## API documents: https://www.ncbi.nlm.nih.gov/books/NBK25499/#chapter4.ESearch\n",
    "## retstart: Sequential index of the first UID in the retrieved set to be shown in the XML output (default = 0)\n",
    "## retmax: Total number of UIDs from the retrieved set to be shown in the XML output (default = 20)\n",
    "## Note: For PubMed, ESearch can only retrieve the first 10,000 records matching the query. \n",
    "##To obtain more than 10,000 PubMed records, consider using <EDirect> that contains \n",
    "## additional logic to batch PubMed search results automatically so that an arbitrary number can be retrieved\n",
    "\n",
    "search_term = \"Acute Myeloid Leukemia[Title/Abstract] AND clinical trial[Publication Type]\"\n",
    "handle = Entrez.esearch(db=\"pubmed\", term=search_term, retmax=10, restart=0)\n",
    "record = Entrez.read(handle)\n",
    "id_list = record[\"IdList\"]\n",
    "\n",
    "## Fetch the details (abstracts) for the articles\n",
    "## retmode: Retrieval mode. This parameter specifies the data format of the records returned, such as plain text, \n",
    "## HMTL or XML. See Table 1 for a full list of allowed values for each database.\n",
    "## Table 1: https://www.ncbi.nlm.nih.gov/books/NBK25499/table/chapter4.T._valid_values_of__retmode_and/?report=objectonly\n",
    "\n",
    "handle = Entrez.efetch(db=\"pubmed\", id=id_list, rettype=\"abstract\", retmode=\"text\")\n",
    "sample_abstract = handle.read()\n",
    "print(sample_abstract)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "0d8b427c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "    \"CLIA_treatment_regimen\": {\n",
      "        \"name\": \"CLIA treatment regimen\",\n",
      "        \"attributes\": {\n",
      "            \"drugs\": [\"cladribine\", \"idarubicin\", \"cytarabine\"],\n",
      "            \"dosage\": {\n",
      "                \"cladribine\": \"5 mg/m² intravenously (days 1-5)\",\n",
      "                \"cytarabine\": \"1000 mg/m² intravenously (days 1-5)\",\n",
      "                \"idarubicin\": \"10 mg/m² intravenously (days 1-3)\"\n",
      "            },\n",
      "            \"additional_treatment\": {\n",
      "                \"drug\": \"sorafenib\",\n",
      "                \"dosage\": \"400 mg twice daily (days 1-14)\",\n",
      "                \"condition\": \"FLT3-mutated AML\"\n",
      "            }\n",
      "        }\n",
      "    },\n",
      "    \"AML\": {\n",
      "        \"name\": \"Acute Myeloid Leukemia (AML)\",\n",
      "        \"attributes\": {\n",
      "            \"type\": \"relapsed and/or refractory\"\n",
      "        }\n",
      "    },\n",
      "    \"edges\": [\n",
      "        {\n",
      "            \"subject\": \"CLIA_treatment_regimen\",\n",
      "            \"predicate\": \"is used to treat\",\n",
      "            \"object\": \"AML\"\n",
      "        },\n",
      "        {\n",
      "            \"subject\": \"CLIA_treatment_regimen\",\n",
      "            \"predicate\": \"includes drugs\",\n",
      "            \"object\": [\"cladribine\", \"idarubicin\", \"cytarabine\"]\n",
      "        }\n",
      "      ]\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "## The expected output is:\n",
    "\n",
    "## Option 1 response\n",
    "# sample_response = \"subject=['acute myeloid leukemia']\\\n",
    "# predicate=['is treated with'] object=['cladribine', 'idarubicin', 'cytarabine']\"\n",
    "\n",
    "## Option 2 response\n",
    "# sample_response = (\n",
    "#     \"'edge': {'subject': 'acute myeloid leukemia', 'predicate': 'is treated with', 'object': 'cladribine'}\\n\"\n",
    "#     \"'edge': {'subject': 'acute myeloid leukemia', 'predicate': 'is treated with', 'object': 'idarubicin'}\\n\"\n",
    "#     \"'edge': {'subject': 'acute myeloid leukemia', 'predicate': 'is treated with', 'object': 'cytarabine'}\"\n",
    "# )\n",
    "\n",
    "sample_response = (\n",
    "    \"\"\"{\n",
    "    \"CLIA_treatment_regimen\": {\n",
    "        \"name\": \"CLIA treatment regimen\",\n",
    "        \"attributes\": {\n",
    "            \"drugs\": [\"cladribine\", \"idarubicin\", \"cytarabine\"],\n",
    "            \"dosage\": {\n",
    "                \"cladribine\": \"5 mg/m² intravenously (days 1-5)\",\n",
    "                \"cytarabine\": \"1000 mg/m² intravenously (days 1-5)\",\n",
    "                \"idarubicin\": \"10 mg/m² intravenously (days 1-3)\"\n",
    "            },\n",
    "            \"additional_treatment\": {\n",
    "                \"drug\": \"sorafenib\",\n",
    "                \"dosage\": \"400 mg twice daily (days 1-14)\",\n",
    "                \"condition\": \"FLT3-mutated AML\"\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    \"AML\": {\n",
    "        \"name\": \"Acute Myeloid Leukemia (AML)\",\n",
    "        \"attributes\": {\n",
    "            \"type\": \"relapsed and/or refractory\"\n",
    "        }\n",
    "    },\n",
    "    \"edges\": [\n",
    "        {\n",
    "            \"subject\": \"CLIA_treatment_regimen\",\n",
    "            \"predicate\": \"is used to treat\",\n",
    "            \"object\": \"AML\"\n",
    "        },\n",
    "        {\n",
    "            \"subject\": \"CLIA_treatment_regimen\",\n",
    "            \"predicate\": \"includes drugs\",\n",
    "            \"object\": [\"cladribine\", \"idarubicin\", \"cytarabine\"]\n",
    "        }\n",
    "      ]\n",
    "}\"\"\"\n",
    ")\n",
    "print(sample_response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "86ca778d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from Bio import Entrez\n",
    "\n",
    "## Provide your email for NCBI\n",
    "Entrez.email = \"qwei@systemsbiology.org\"\n",
    "\n",
    "## Search PubMed for articles related to \"Acute Myeloid Leukemia\"\n",
    "## API documents: https://www.ncbi.nlm.nih.gov/books/NBK25499/#chapter4.ESearch\n",
    "## retstart: Sequential index of the first UID in the retrieved set to be shown in the XML output (default = 0)\n",
    "## retmax: Total number of UIDs from the retrieved set to be shown in the XML output (default = 20)\n",
    "## Note: For PubMed, ESearch can only retrieve the first 10,000 records matching the query. \n",
    "##To obtain more than 10,000 PubMed records, consider using <EDirect> that contains \n",
    "## additional logic to batch PubMed search results automatically so that an arbitrary number can be retrieved\n",
    "\n",
    "search_term = \"Acute Myeloid Leukemia[Title/Abstract] AND clinical trial[Publication Type]\"\n",
    "handle = Entrez.esearch(db=\"pubmed\", term=search_term, retmax=71, restart=1)\n",
    "record = Entrez.read(handle)\n",
    "id_list = record[\"IdList\"]\n",
    "\n",
    "## Fetch the details (abstracts) for the articles\n",
    "## retmode: Retrieval mode. This parameter specifies the data format of the records returned, such as plain text, \n",
    "## HMTL or XML. See Table 1 for a full list of allowed values for each database.\n",
    "## Table 1: https://www.ncbi.nlm.nih.gov/books/NBK25499/table/chapter4.T._valid_values_of__retmode_and/?report=objectonly\n",
    "\n",
    "handle = Entrez.efetch(db=\"pubmed\", id=id_list, rettype=\"abstract\", retmode=\"text\")\n",
    "abstracts = handle.read()\n",
    "# print(abstracts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "c6faa262",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{ \"edge\": { \"subject\": \"Hematology\", \"predicate\": \"is_relevant_for\", \"object\": \"AML\" } }\n",
      "       \t\t\t\t\t   \t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"health\", \"predicate\": \"is_related_to\", \"object\": \"cancer\" } } \n",
      "{ \"edge\": {\"subject\": \"AML\", \"predicate\": \"is treated with\", \"object\": \"Haplo-cord HCT\" }}\n",
      "   \t\t\t\t\t\t\t  \t\t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"showed positive result in study about\", \"object\": \"Haplo-cord HCT\" } }\n",
      "        \t\t\t\t\t\t\t\t\t\t  \n",
      "{ \"edge\": { \"subject\": \"Acute Myeloid Leukemia\", \"predicate\": \"is treated by\", \"object\": \"Haplo-cord hematopoietic cell transplantation\" } }\n",
      "  \t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t\t\n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"is treated by\", \"object\": \"Haplo-cord HCT\" } }\n",
      "   \t\t   \t\t\t\t\t\t\t    \t\n",
      "{ \"edge\": {\"subject\":\"Hematology\",\"predicate\":\"is_about\",\"object\":\"Acute Myeloid Leukemia\"} }\n",
      "    \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"aml\", \"predicate\": \"better than\", \"object\": \"haplo-HCT\" } } \n",
      "{ \"edge\": {\"subject\": \"Blood Diseases and Disorders\", \"predicate\": \"isRelatedTo\", \"object\": \"Hematology\"} }\n",
      "              \t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"Hematology\", \"predicate\": \"treat\", \"object\": \"Leukemia\" } } \n",
      "{ \"edge\": { \"subject\": \"Hematology\", \"predicate\": \"is_about\", \"object\": \"Cancer\" } }\n",
      "    \t\t\t\t\t  \t\t\t\t    \t\n",
      "{ \"edge\": { \"subject\": \"medicine\", \"predicate\": \"treat\", \"object\": \"AML\" } }\n",
      "     \t\t\t\t\t  \t\t\t\t\t\t  \n",
      "{ \"edge\": { \"subject\": \"Hematology\", \"predicate\": \"isRelevantTo\", \"object\": \"Acute Myeloid Leukemia (AML)\" } }\n",
      "  \t\t\t\t\t\t\t\t\t\t  \t\t\t\t\t\n",
      "{ \"edge\": {\n",
      "    \"subject\": \"Acute myeloid leukemia\",\n",
      "    \"predicate\": \"is_treated_by\",\n",
      "    \"object\": \"Haplo-cord hematopoietic cell transplantation\"\n",
      "}}\n",
      "     \t\t\t            \n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"may be treated with\", \"object\": \"Haplo-cord HCT\" } }\n",
      "    \t\t\t\t\t\t\t    \n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"increases\", \"object\": \"OS\" } }\n",
      "   \t\t\t\t\t\t\t\t\t\t  \t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"Health Sciences\", \"predicate\": \"relates to\", \"object\": \"Acute Myeloid Leukemia\" } }\n",
      "   \t\t\t\t\t\t   \t\t\t    \t\n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"has study\", \"object\": \"Haplo-cord HCT\" } }\n",
      "   \t\t\t\t\t \t\t\t\t\t\t\t\t\t \n",
      "{ \"edge\": { \"subject\": \"Health Sciences\", \"predicate\": \"isRelevantTo\", \"object\": \"Cancer\" } } \n",
      "{ \"edge\": { \"subject\": \"Acute Myeloid Leukemia\", \"predicate\": \"has\", \"object\": \"Haploidentical Hematopoietic Cell Transplantation\" } }\n",
      "   \t\t\t\t\t   \t\t\t\t\t\n",
      "{ \"edge\" : {\n",
      "   \"subject\": \"Cord Blood Transplantation in AML\",\n",
      "   \"predicate\": \"isTreatmentFor\",\n",
      "   \"object\": \"Acute Myeloid Leukemia\"\n",
      "} }\n",
      "  \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": \"AML\", \"predicate\": \"has_drug_treatment\", \"object\": \"Haplo-cord HCT\" } }\n",
      "   \t\t\t\t\t\t\t\t\t  \t\t  \n",
      "{ \"edge\": { \"subject\": \"Acute Myeloid Leukemia\", \"predicate\": \"has_drug\", \"object\": \"Immunotherapy\" } }\n",
      "   \t\t\t\t\t\t\t\t\t\t\t\t\t\t\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[10], line 27\u001b[0m\n\u001b[1;32m     25\u001b[0m \u001b[38;5;66;03m## Set a fix number of potential responses\u001b[39;00m\n\u001b[1;32m     26\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[38;5;241m70\u001b[39m):\n\u001b[0;32m---> 27\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mollama\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m     28\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mdeepseek-r1:14b\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     29\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[1;32m     30\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are a helpful assistant in biomedical research:\u001b[39;49m\u001b[38;5;130;43;01m\\\u001b[39;49;00m\n\u001b[1;32m     31\u001b[0m \u001b[38;5;124;43m                                        extracting all possible / potential edges (e.g. between protein, genes, diseases)\u001b[39;49m\u001b[38;5;130;43;01m\\\u001b[39;49;00m\n\u001b[1;32m     32\u001b[0m \u001b[38;5;124;43m                                        from given abstracts for each paper\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     33\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mPlease provide answers satisfing following relationship:\u001b[39;49m\u001b[38;5;130;43;01m\\\u001b[39;49;00m\n\u001b[1;32m     34\u001b[0m \u001b[38;5;124;43m                                            subject -> predicate -> object\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     35\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mQ:Based on this abstract, \u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[43msample_abstract\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mA:\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m \u001b[49m\u001b[38;5;241;43m+\u001b[39;49m\u001b[43m \u001b[49m\u001b[43msample_response\u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     36\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mabstracts\u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     37\u001b[0m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     38\u001b[0m \u001b[43m          \u001b[49m\u001b[38;5;28;43mformat\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mEdges\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmodel_json_schema\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     39\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;66;43;03m#     options={'temperature': 70},  # temp = 0: Makes responses more deterministic\u001b[39;49;00m\n\u001b[1;32m     40\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m     41\u001b[0m     \u001b[38;5;28mprint\u001b[39m(response[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessage\u001b[39m\u001b[38;5;124m\"\u001b[39m][\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcontent\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/ollama/_client.py:333\u001b[0m, in \u001b[0;36mClient.chat\u001b[0;34m(self, model, messages, tools, stream, format, options, keep_alive)\u001b[0m\n\u001b[1;32m    289\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mchat\u001b[39m(\n\u001b[1;32m    290\u001b[0m   \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m    291\u001b[0m   model: \u001b[38;5;28mstr\u001b[39m \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m'\u001b[39m\u001b[38;5;124m'\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    298\u001b[0m   keep_alive: Optional[Union[\u001b[38;5;28mfloat\u001b[39m, \u001b[38;5;28mstr\u001b[39m]] \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m    299\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m Union[ChatResponse, Iterator[ChatResponse]]:\n\u001b[1;32m    300\u001b[0m \u001b[38;5;250m  \u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m    301\u001b[0m \u001b[38;5;124;03m  Create a chat response using the requested model.\u001b[39;00m\n\u001b[1;32m    302\u001b[0m \n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    331\u001b[0m \u001b[38;5;124;03m  Returns `ChatResponse` if `stream` is `False`, otherwise returns a `ChatResponse` generator.\u001b[39;00m\n\u001b[1;32m    332\u001b[0m \u001b[38;5;124;03m  \"\"\"\u001b[39;00m\n\u001b[0;32m--> 333\u001b[0m   \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    334\u001b[0m \u001b[43m    \u001b[49m\u001b[43mChatResponse\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    335\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mPOST\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    336\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43m/api/chat\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    337\u001b[0m \u001b[43m    \u001b[49m\u001b[43mjson\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatRequest\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    338\u001b[0m \u001b[43m      \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    339\u001b[0m \u001b[43m      \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43mmessage\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mmessage\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m_copy_messages\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m)\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    340\u001b[0m \u001b[43m      \u001b[49m\u001b[43mtools\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43mtool\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mtool\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43m_copy_tools\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtools\u001b[49m\u001b[43m)\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    341\u001b[0m \u001b[43m      \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    342\u001b[0m \u001b[43m      \u001b[49m\u001b[38;5;28;43mformat\u001b[39;49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mformat\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    343\u001b[0m \u001b[43m      \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moptions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    344\u001b[0m \u001b[43m      \u001b[49m\u001b[43mkeep_alive\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mkeep_alive\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    345\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmodel_dump\u001b[49m\u001b[43m(\u001b[49m\u001b[43mexclude_none\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    346\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    347\u001b[0m \u001b[43m  \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/ollama/_client.py:178\u001b[0m, in \u001b[0;36mClient._request\u001b[0;34m(self, cls, stream, *args, **kwargs)\u001b[0m\n\u001b[1;32m    174\u001b[0m         \u001b[38;5;28;01myield\u001b[39;00m \u001b[38;5;28mcls\u001b[39m(\u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mpart)\n\u001b[1;32m    176\u001b[0m   \u001b[38;5;28;01mreturn\u001b[39;00m inner()\n\u001b[0;32m--> 178\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mcls\u001b[39m(\u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_request_raw\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\u001b[38;5;241m.\u001b[39mjson())\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/ollama/_client.py:118\u001b[0m, in \u001b[0;36mClient._request_raw\u001b[0;34m(self, *args, **kwargs)\u001b[0m\n\u001b[1;32m    116\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21m_request_raw\u001b[39m(\u001b[38;5;28mself\u001b[39m, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs):\n\u001b[1;32m    117\u001b[0m   \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 118\u001b[0m     r \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    119\u001b[0m     r\u001b[38;5;241m.\u001b[39mraise_for_status()\n\u001b[1;32m    120\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m r\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_client.py:837\u001b[0m, in \u001b[0;36mClient.request\u001b[0;34m(self, method, url, content, data, files, json, params, headers, cookies, auth, follow_redirects, timeout, extensions)\u001b[0m\n\u001b[1;32m    822\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(message, \u001b[38;5;167;01mDeprecationWarning\u001b[39;00m)\n\u001b[1;32m    824\u001b[0m request \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mbuild_request(\n\u001b[1;32m    825\u001b[0m     method\u001b[38;5;241m=\u001b[39mmethod,\n\u001b[1;32m    826\u001b[0m     url\u001b[38;5;241m=\u001b[39murl,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    835\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mextensions,\n\u001b[1;32m    836\u001b[0m )\n\u001b[0;32m--> 837\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mauth\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mauth\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_client.py:926\u001b[0m, in \u001b[0;36mClient.send\u001b[0;34m(self, request, stream, auth, follow_redirects)\u001b[0m\n\u001b[1;32m    922\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_set_timeout(request)\n\u001b[1;32m    924\u001b[0m auth \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_build_request_auth(request, auth)\n\u001b[0;32m--> 926\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_auth\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    927\u001b[0m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    928\u001b[0m \u001b[43m    \u001b[49m\u001b[43mauth\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mauth\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    929\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    930\u001b[0m \u001b[43m    \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    931\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    932\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    933\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m stream:\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_client.py:954\u001b[0m, in \u001b[0;36mClient._send_handling_auth\u001b[0;34m(self, request, auth, follow_redirects, history)\u001b[0m\n\u001b[1;32m    951\u001b[0m request \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mnext\u001b[39m(auth_flow)\n\u001b[1;32m    953\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 954\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_redirects\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    955\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    956\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    957\u001b[0m \u001b[43m        \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhistory\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    958\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    959\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    960\u001b[0m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_client.py:991\u001b[0m, in \u001b[0;36mClient._send_handling_redirects\u001b[0;34m(self, request, follow_redirects, history)\u001b[0m\n\u001b[1;32m    988\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrequest\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n\u001b[1;32m    989\u001b[0m     hook(request)\n\u001b[0;32m--> 991\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_single_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    992\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    993\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_client.py:1027\u001b[0m, in \u001b[0;36mClient._send_single_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m   1022\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[1;32m   1023\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAttempted to send an async request with a sync Client instance.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1024\u001b[0m     )\n\u001b[1;32m   1026\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m request_context(request\u001b[38;5;241m=\u001b[39mrequest):\n\u001b[0;32m-> 1027\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mtransport\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1029\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, SyncByteStream)\n\u001b[1;32m   1031\u001b[0m response\u001b[38;5;241m.\u001b[39mrequest \u001b[38;5;241m=\u001b[39m request\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpx/_transports/default.py:236\u001b[0m, in \u001b[0;36mHTTPTransport.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    223\u001b[0m req \u001b[38;5;241m=\u001b[39m httpcore\u001b[38;5;241m.\u001b[39mRequest(\n\u001b[1;32m    224\u001b[0m     method\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mmethod,\n\u001b[1;32m    225\u001b[0m     url\u001b[38;5;241m=\u001b[39mhttpcore\u001b[38;5;241m.\u001b[39mURL(\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    233\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    234\u001b[0m )\n\u001b[1;32m    235\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_httpcore_exceptions():\n\u001b[0;32m--> 236\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_pool\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mreq\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    238\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(resp\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n\u001b[1;32m    240\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m Response(\n\u001b[1;32m    241\u001b[0m     status_code\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mstatus,\n\u001b[1;32m    242\u001b[0m     headers\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m    243\u001b[0m     stream\u001b[38;5;241m=\u001b[39mResponseStream(resp\u001b[38;5;241m.\u001b[39mstream),\n\u001b[1;32m    244\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    245\u001b[0m )\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/connection_pool.py:256\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    253\u001b[0m         closing \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_assign_requests_to_connections()\n\u001b[1;32m    255\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_close_connections(closing)\n\u001b[0;32m--> 256\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    258\u001b[0m \u001b[38;5;66;03m# Return the response. Note that in this case we still have to manage\u001b[39;00m\n\u001b[1;32m    259\u001b[0m \u001b[38;5;66;03m# the point at which the response is closed.\u001b[39;00m\n\u001b[1;32m    260\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/connection_pool.py:236\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    232\u001b[0m connection \u001b[38;5;241m=\u001b[39m pool_request\u001b[38;5;241m.\u001b[39mwait_for_connection(timeout\u001b[38;5;241m=\u001b[39mtimeout)\n\u001b[1;32m    234\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    235\u001b[0m     \u001b[38;5;66;03m# Send the request on the assigned connection.\u001b[39;00m\n\u001b[0;32m--> 236\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mconnection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    237\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpool_request\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\n\u001b[1;32m    238\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    239\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m ConnectionNotAvailable:\n\u001b[1;32m    240\u001b[0m     \u001b[38;5;66;03m# In some cases a connection may initially be available to\u001b[39;00m\n\u001b[1;32m    241\u001b[0m     \u001b[38;5;66;03m# handle a request, but then become unavailable.\u001b[39;00m\n\u001b[1;32m    242\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    243\u001b[0m     \u001b[38;5;66;03m# In this case we clear the connection and try again.\u001b[39;00m\n\u001b[1;32m    244\u001b[0m     pool_request\u001b[38;5;241m.\u001b[39mclear_connection()\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/connection.py:103\u001b[0m, in \u001b[0;36mHTTPConnection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    100\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connect_failed \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[1;32m    101\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc\n\u001b[0;32m--> 103\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_connection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/http11.py:136\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    134\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m Trace(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse_closed\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    135\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_response_closed()\n\u001b[0;32m--> 136\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m exc\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/http11.py:106\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m     95\u001b[0m     \u001b[38;5;28;01mpass\u001b[39;00m\n\u001b[1;32m     97\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m Trace(\n\u001b[1;32m     98\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mreceive_response_headers\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request, kwargs\n\u001b[1;32m     99\u001b[0m ) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    100\u001b[0m     (\n\u001b[1;32m    101\u001b[0m         http_version,\n\u001b[1;32m    102\u001b[0m         status,\n\u001b[1;32m    103\u001b[0m         reason_phrase,\n\u001b[1;32m    104\u001b[0m         headers,\n\u001b[1;32m    105\u001b[0m         trailing_data,\n\u001b[0;32m--> 106\u001b[0m     ) \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_response_headers\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    107\u001b[0m     trace\u001b[38;5;241m.\u001b[39mreturn_value \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m    108\u001b[0m         http_version,\n\u001b[1;32m    109\u001b[0m         status,\n\u001b[1;32m    110\u001b[0m         reason_phrase,\n\u001b[1;32m    111\u001b[0m         headers,\n\u001b[1;32m    112\u001b[0m     )\n\u001b[1;32m    114\u001b[0m network_stream \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_network_stream\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/http11.py:177\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_response_headers\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    174\u001b[0m timeout \u001b[38;5;241m=\u001b[39m timeouts\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mread\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[1;32m    176\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 177\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_event\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    178\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(event, h11\u001b[38;5;241m.\u001b[39mResponse):\n\u001b[1;32m    179\u001b[0m         \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_sync/http11.py:217\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_event\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    214\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mnext_event()\n\u001b[1;32m    216\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m event \u001b[38;5;129;01mis\u001b[39;00m h11\u001b[38;5;241m.\u001b[39mNEED_DATA:\n\u001b[0;32m--> 217\u001b[0m     data \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_network_stream\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    218\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mREAD_NUM_BYTES\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[1;32m    219\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    221\u001b[0m     \u001b[38;5;66;03m# If we feed this case through h11 we'll raise an exception like:\u001b[39;00m\n\u001b[1;32m    222\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    223\u001b[0m     \u001b[38;5;66;03m#     httpcore.RemoteProtocolError: can't handle event type\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    227\u001b[0m     \u001b[38;5;66;03m# perspective. Instead we handle this case distinctly and treat\u001b[39;00m\n\u001b[1;32m    228\u001b[0m     \u001b[38;5;66;03m# it as a ConnectError.\u001b[39;00m\n\u001b[1;32m    229\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m data \u001b[38;5;241m==\u001b[39m \u001b[38;5;124mb\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mtheir_state \u001b[38;5;241m==\u001b[39m h11\u001b[38;5;241m.\u001b[39mSEND_RESPONSE:\n",
      "File \u001b[0;32m/opt/homebrew/Caskroom/miniforge/base/envs/pytorch_env/lib/python3.11/site-packages/httpcore/_backends/sync.py:128\u001b[0m, in \u001b[0;36mSyncStream.read\u001b[0;34m(self, max_bytes, timeout)\u001b[0m\n\u001b[1;32m    126\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_exceptions(exc_map):\n\u001b[1;32m    127\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sock\u001b[38;5;241m.\u001b[39msettimeout(timeout)\n\u001b[0;32m--> 128\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrecv\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmax_bytes\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "## Ollama's notes on how to create structured output\n",
    "## https://ollama.com/blog/structured-outputs\n",
    "from pydantic import BaseModel\n",
    "# from typing import List\n",
    "\n",
    "## Option 1\n",
    "# class Edges(BaseModel):\n",
    "#     subject: list[str]\n",
    "#     predicate: list[str]\n",
    "#     object: list[str]\n",
    "\n",
    "## Option 2\n",
    "## add a desired Pubmed id\n",
    "## add a desired clinical trial id\n",
    "class Edge(BaseModel):\n",
    "    subject: str\n",
    "    predicate: str\n",
    "    object: str\n",
    "\n",
    "class Edges(BaseModel):\n",
    "    edge: Edge\n",
    "\n",
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "## Set a fix number of potential responses\n",
    "for i in range(70):\n",
    "    response = ollama.chat(\n",
    "        model=\"deepseek-r1:14b\",\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting all possible / potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts for each paper\"},\n",
    "            {\"role\": \"system\", \"content\": \"Please provide answers satisfing following relationship:\\\n",
    "                                            subject -> predicate -> object\"},\n",
    "            {\"role\": \"system\", \"content\": \"Q:Based on this abstract, \" + sample_abstract + \"A:\" + sample_response},\n",
    "            {\"role\": \"user\", \"content\": abstracts},\n",
    "        ],\n",
    "          format=Edges.model_json_schema(),\n",
    "    #     options={'temperature': 70},  # temp = 0: Makes responses more deterministic\n",
    "    )\n",
    "    print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "c19aa347",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{ \"edge\": { \"subject\": { \"name\": \"急性髓性白血病\", \"attributes\": { \"Drugs\": [\"达沙替尼\"], \"Type\": \"成人白血病\" } }, \"predicate\": \"与...相关\", \"object\": { \"name\": \"细胞免疫治疗\", \"attributes\": { \"Drugs\": [\"伊马替尼\"] ,\"Type\": \"儿童白血病\" } } } }\n",
      "  \t\t\t\t\t\t\t   \t\t\t\t\n",
      "{ \"edge\": { \"subject\": { \"name\": \"AML\", \"attributes\": { \"Drugs\": [\"Lenalidomide\"] , \"Type\": \"Acute leukemia\" } }, \"predicate\": \"IS_TREATED_WITH\", \"object\": { \"name\": \"Haplo-cord Hematopoietic Cell Transplantation (HCT)\", \"attributes\": { \"Drugs\": [\"Bortezomib\"] , \"Type\": \"Hematopoietic stem cell transplantation\" } } } }\n",
      "   \t\t\t\t\t\t\t   \t\t\t\t\t\t\t\n",
      "{ \"edge\": {\"subject\": {\"name\": \"AML\", \"attributes\": {\"Drugs\": [\"Immunosuppressive drugs\"], \"Type\": \"Acute myeloid leukemia\"}}, \"predicate\": \"treated_with\", \"object\": {\"name\": \"Immunosuppressive drugs\", \"attributes\": {\"Drugs\": [\"Cyclophosphamide\", \"Cyclosporine\"] , \"Type\": \"Immunosuppressant\"}}} }\n",
      "   \t\t\t\t\t\t\t\t\t\t  \t\t\t  \n",
      "{ \"edge\" : { \"subject\" : { \"name\" : \"急性白血病\", \"attributes\": { \"Drugs\": [\"吉西他滨\",\"伊马替尼\"], \"Type\": \"AML\" } }, \"predicate\": \"研究\", \"object\": { \"name\": \"苏州大学附属医院\", \"attributes\": { \"Drugs\": [\"吉西他滨\",\"伊马替尼\"] , \"Type\": \" clinical trial\"} } } }\n",
      "   \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": {\n",
      "    \"subject\": {\n",
      "        \"name\": \"急性髓系白血病\",\n",
      "        \"attributes\": {\n",
      "            \"Drugs\": [\"Midostaurin\", \"Risparima\"],\n",
      "            \"Type\": \"AML\"\n",
      "        }\n",
      "    },\n",
      "    \"predicate\": \"=\",\n",
      "    \"object\": {\n",
      "        \"name\": \"治疗方案\",\n",
      "        \"attributes\": {\n",
      "            \"Drugs\": [\"Midostaurin\", \"Risparima\"]\n",
      "        ,\n",
      "            \"Type\": \"Treatment Plan\"\n",
      "        }\n",
      "    }\n",
      "}\n",
      "} \n",
      "{ \"edge\": { \"subject\": { \"name\": \"急性髓性白血病\", \"attributes\": { \"Drugs\": [\"药物A\", \"药物B\"] , \"Type\": \"成人患者\" } }, \"predicate\": \"研究\", \"object\": { \"name\": \"治疗效果\", \"attributes\": { \"Drugs\": [\"药物C\", \"药物D\"], \"Type\": \"儿童患者\" } } } }\n",
      "   \t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": {\"subject\": {\"name\": \"Acute Myeloid Leukemia\", \"attributes\": {\"Drugs\": [\"Fluorouracil\"], \"Type\": \"hematologic\"}}, \"predicate\": \"is_treated_with\", \"object\": {\"name\": \"Haplo-cord Hematopoietic Cell Transplantation\", \"attributes\": {\"Drugs\": [\"Cyclophosphamide\"], \"Type\": \"hematopoietic procedure\"}} } }\n",
      "  \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": { \"name\": \"急性髓系白血病\", \"attributes\": {\"Drugs\": [\"替吉奥\", \"达沙替尼\"], \"Type\": \"AML\"} }, \"predicate\": \"治疗方案\", \"object\": { \"name\": \"造血干细胞移植\", \"attributes\": {\"Drugs\": [\"阿扎胞苷\"], \"Type\": \"HCT\"} } } }\n",
      "  \t\t   \t\t\t\t\t    \t\t\t\t\n",
      "{ \"edge\": {\"subject\": {\"name\": \"AML\", \"attributes\": {\"Drugs\": [\"Immunotherapy\"], \"Type\": \"acute leukemia\"}},\"predicate\": \"is_treated_with\",\"object\": {\"name\": \"Haploidentical cord blood HCT\", \"attributes\": {\"Drugs\": [\"Cord Blood Stem Cells\"], \"Type\": \"stem cell transplant\"}}} } \n",
      "{ \"edge\": {\"subject\": {\"name\": \"Acute Myeloid Leukemia\", \"attributes\": {\"Drugs\": [\"Venetoclax\"], \"Type\": \"Adult\"}},\"predicate\": \"is_related_to\", \"object\": {\"name\": \"Childhood Cancers\", \"attributes\": { \"Drugs\": [\"Immunotherapy\"] , \"Type\": \"Pediatric\" }}}} \n"
     ]
    }
   ],
   "source": [
    "## Ollama's notes on how to create structured output\n",
    "## https://ollama.com/blog/structured-outputs\n",
    "from pydantic import BaseModel\n",
    "# from typing import List\n",
    "\n",
    "## Option 1\n",
    "# class Edges(BaseModel):\n",
    "#     subject: list[str]\n",
    "#     predicate: list[str]\n",
    "#     object: list[str]\n",
    "\n",
    "## Option 2\n",
    "## add a desired Pubmed id\n",
    "## add a desired clinical trial id\n",
    "class Attributes(BaseModel):\n",
    "    Note:list[str]\n",
    "    Type: str\n",
    "    \n",
    "class Node(BaseModel):\n",
    "    name:str\n",
    "    attributes: Attributes\n",
    "\n",
    "class Edge(BaseModel):\n",
    "    subject: Node\n",
    "    predicate: str\n",
    "    object: Node\n",
    "\n",
    "class Edges(BaseModel):\n",
    "    edge: Edge\n",
    "\n",
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "## Set a fix number of potential responses\n",
    "for i in range(10):\n",
    "    response = ollama.chat(\n",
    "        model=\"deepseek-r1:14b\",\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting all possible / potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts for each paper\"},\n",
    "            {\"role\": \"system\", \"content\": \"Please provide answers satisfing following relationship:\\\n",
    "                                            subject -> predicate -> object\"},\n",
    "            {\"role\": \"system\", \"content\": \"Q:Based on this abstract, \" + sample_abstract + \"A:\" + sample_response},\n",
    "            {\"role\": \"user\", \"content\": abstracts},\n",
    "        ],\n",
    "          format=Edges.model_json_schema(),\n",
    "    #     options={'temperature': 70},  # temp = 0: Makes responses more deterministic\n",
    "    )\n",
    "    print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "372e9b24",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{ \"edge\": { \"subject\": { \"name\": \"Leukemia\", \"attributes\": { \"Note\": [ \"Hematopoietic malignancy\" ] , \"Type\": \"acute myeloid leukemia (AML)\" } }, \"predicate\": \"is a type of\", \"object\": { \"name\": \"Disease\", \"attributes\": { \"Note\": [ \"Cancer\" ] , \"Type\": \"Malignant neoplasm\" } } } }\n",
      "   \t\t\t\t\t\t\t   \t\t\t\t\t\t\t\n",
      "{ \"edge\" : {\"subject\": {\"name\": \"急性髓性白血病（AML）\", \"attributes\": {\"Note\": [\"AML是成人中常见和致命的血液系统恶性肿瘤。治疗方案包括化疗、靶向治疗和造血干细胞移植。\"] ,\"Type\": \"疾病\" } }, \"predicate\": \"提出解决方案\", \"object\": { \"name\": \"异基因造血干细胞移植（allo-HSCT）\", \"attributes\": {\"Note\": [\"allo-HSCT是AML患者的主要治疗方法之一，特别是对于年轻且适合的患者。\"], \"Type\": \"治疗方案\" }} } }\n",
      "   \t\t\t\t\t  \t\t\t\t\t  \t\t \n",
      "{ \"edge\": { \"subject\": { \"name\": \"acute myeloid leukemia\", \"attributes\": { \"Note\": [ \"Note: acute myeloid leukemia is a type of blood and bone marrow cancer.\" ] ,\"Type\": \"leukemia\" } }, \"predicate\": \"has therapu_2019\", \"object\": { \"name\": \"Immunotherapy药物治疗\", \"attributes\": { \"Note\": [ \"Note: 免疫疗法是一种利用人体免疫系统来对抗疾病的方法。\" ] ,\"Type\": \"therapeutic method\" } } } }\n",
      "               \t\t\t\n",
      "{ \"edge\" : { \"subject\": { \"name\": \"Acute Myeloid Leukemia\", \"attributes\": { \"Note\": [ \"AML is a type of blood cancer that starts in the myeloid cells.\", \"It affects about 1 in 100,000 people annually.\", \"Treatment options include chemotherapy, radiation therapy, and stem cell transplant.\" ] , \"Type\": \"Cancer\" } }, \"predicate\": \"is treated with\", \"object\": { \"name\": \"Stem Cell Transplantation\", \"attributes\": { \"Note\": [ \"A medical procedure where a patient receives healthy stem cells from a donor.\", \"It is used to treat diseases like leukemia, lymphoma, and other blood disorders.\", \"The process includes harvesting, processing, and transplanting of stem cells.\" ] , \"Type\": \"Treatment\" } } }\n",
      "}\n",
      "   \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n",
      "{ \"edge\": {\"subject\": {\"name\": \"Acute Myeloid Leukemia (AML)\", \"attributes\": {\"Note\": [\"Important study on the treatment of AML using haplo-cord HCT\", \"Highlighted better OS and PFS in this method compared to haplo-HCT\"] , \"Type\": \"Therapy Study\"} },\"predicate\": \"shows\", \"object\": {\"name\": \"Haplo-cord Hematopoietic Cell Transplantation (Haplo-cord HCT)\", \"attributes\": {\"Note\":[\"Significantly improves survival outcomes in AML patients\",\"Has comparable adverse effects to standard Haplo-HCT\"], \"Type\":\"Therapy Study\" } } } }\n",
      "   \t\t\t\t\t\t\t   \t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": { \"name\": \"急性白血病\", \"attributes\": { \"Note\": [ \"This paper is about a new treatment for acute myeloid leukemia (AML) using haplo-cord HCT, which showed better survival rates than traditional haplo-HCT.\" ] , \"Type\": \"Acute Myeloid Leukemia\" } }, \"predicate\": \"treats\", \"object\": { \"name\": \"骨髓移植\", \"attributes\": { \"Note\": [ \"This study uses a type of bone marrow transplant called haplo-cord HCT, which combines half-matched donor cells with cord blood to treat AML.\" ] , \"Type\": \"Bone Marrow Transplant\" } } } }\n",
      "   \t\t\t\t\t\t\t\t  \t\t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": { \"name\": \"aml\", \"attributes\": { \"Note\": [ \"acute myeloid leukemia\" ] , \"Type\": \"Cancer\" } }, \"predicate\": \"is treated with\", \"object\": { \"name\": \"Haplo-cord HCT\", \"attributes\": { \"Note\": [ \"haploidentical cord blood transplant\" ], \"Type\": \"Procedure\" } } } }\n",
      "   \t\t\t\t\t\t\t   \t\t\t\t\t\n",
      "{ \"edge\": {\"subject\": {\"name\": \"Acute Myeloid Leukemia\", \"attributes\": {\"Note\": [\"AML\"] , \"Type\": \"Cancer\"}}, \"predicate\": \"has\", \"object\": {\"name\": \"Haplo-Cord Transplantation\", \"attributes\": {\"Note\": [\"Haplo-Cord HCT\"], \"Type\": \"Treatment\"}}} }\n",
      "    \t\t\t\t\t\t\t   \t\t\t\t\t\t\n",
      "{ \"edge\": { \"subject\": { \"name\": \"Acute myeloid leukemia (AML)\", \"attributes\": { \"Note\": [ \"Haplo-cord HCT group had a higher overall survival rate compared to haplo-HCT group in AML patients.\" ] , \"Type\": \"Observational study\" } }, \"predicate\": \"is associated with\", \"object\": { \"name\": \"Overall Survival (OS)\", \"attributes\": { \"Note\": [ \"Haplo-cord HCT demonstrated a 3-year OS of 80.5% versus 67.8% in the haplo-HCT group.\" ] , \"Type\": \"Outcome measure\" } } } }\n",
      "                    \n",
      "{ \"edge\": { \"subject\": { \"name\": \"Acute myeloid leukemia\", \"attributes\": { \"Note\": [ \"AML is a type of blood cancer that starts in the bone marrow.\" ] , \"Type\": \"cancer\" } }, \"predicate\": \"is treated with\", \"object\": { \"name\": \"Haploidentical hematopoietic cell transplantation (Haplo-HCT)\", \"attributes\": { \"Note\": [ \"Haplo-HCT uses stem cells from a donor whose genetic makeup is only partially matched to the recipient.\" ] , \"Type\": \"treatment\" } } } }\n",
      "   \t\t\t\t\t\t\t  \t\t\t\t\t\n"
     ]
    }
   ],
   "source": [
    "## Ollama's notes on how to create structured output\n",
    "## https://ollama.com/blog/structured-outputs\n",
    "from pydantic import BaseModel\n",
    "# from typing import List\n",
    "\n",
    "## Option 1\n",
    "# class Edges(BaseModel):\n",
    "#     subject: list[str]\n",
    "#     predicate: list[str]\n",
    "#     object: list[str]\n",
    "\n",
    "## Option 2\n",
    "## add a desired Pubmed id\n",
    "## add a desired clinical trial id\n",
    "class Attributes(BaseModel):\n",
    "    Note:list[str]\n",
    "    Type: str\n",
    "    \n",
    "class Node(BaseModel):\n",
    "    name:str\n",
    "    attributes: Attributes\n",
    "\n",
    "class Edge(BaseModel):\n",
    "    subject: Node\n",
    "    predicate: str\n",
    "    object: Node\n",
    "\n",
    "class Edges(BaseModel):\n",
    "    edge: Edge\n",
    "\n",
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "## Set a fix number of potential responses\n",
    "for i in range(10):\n",
    "    response = ollama.chat(\n",
    "        model=\"deepseek-r1:14b\",\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting all possible / potential edges (e.g. between protein, genes, diseases)\\\n",
    "                                        from given abstracts for each paper\"},\n",
    "            {\"role\": \"system\", \"content\": \"Please provide answers satisfing following relationship:\\\n",
    "                                            subject -> predicate -> object\"},\n",
    "            {\"role\": \"system\", \"content\": \"Q:Based on this abstract, \" + sample_abstract + \"A:\" + sample_response},\n",
    "            {\"role\": \"user\", \"content\": abstracts},\n",
    "        ],\n",
    "          format=Edges.model_json_schema(),\n",
    "    #     options={'temperature': 70},  # temp = 0: Makes responses more deterministic\n",
    "    )\n",
    "    print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "adbcd983",
   "metadata": {},
   "outputs": [],
   "source": [
    "## Ollama's notes on how to create structured output\n",
    "## https://ollama.com/blog/structured-outputs\n",
    "from pydantic import BaseModel\n",
    "# from typing import List\n",
    "\n",
    "class Subject(BaseModel):\n",
    "    subject_name: str\n",
    "#     subject_type: str\n",
    "\n",
    "class Object(BaseModel):\n",
    "    object_name: str\n",
    "#     object_type: str\n",
    "\n",
    "class Predicate(BaseModel):\n",
    "    predicate_name: str\n",
    "\n",
    "    \n",
    "class Edges(BaseModel):\n",
    "    edge: list[[Subject, Predicate, Object]]\n",
    "    \n",
    "\n",
    "## 1. Prompt engineering method\n",
    "import ollama\n",
    "response = ollama.chat(\n",
    "    model=\"deepseek-r1:14b\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant in biomedical research:\\\n",
    "                                        extracting all potential edges (e.g. between protein, genes, diseases, medications, compounds)\\\n",
    "                                        from given abstracts for each paper\"},\n",
    "#         {\"role\": \"system\", \"content\": \"Please note that there are multiple abstracts, each starts with number 1., 2., 3., etc.\"},\n",
    "#         {\"role\": \"system\", \"content\": \"Please provide a final answer in following format:\\\n",
    "#                                         subject -> predicate -> object\"},\n",
    "        {\"role\": \"user\", \"content\": abstracts},\n",
    "        {\"role\": \"user\", \"content\": 'I have provided you with 2 abstracts. Return a list of edges.'},\n",
    "    ],\n",
    "    format=Edges.model_json_schema(),\n",
    "    options={'temperature': 0},  # Make responses more deterministic\n",
    ")\n",
    "print(response[\"message\"][\"content\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6bda7ec2",
   "metadata": {},
   "outputs": [],
   "source": [
    "## 3. fine tuning with FDA drugs\n",
    "\n",
    "## drug or drug combination\n",
    "## or diseases "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "44777684",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "97d66765",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (pytorch_env)",
   "language": "python",
   "name": "pytorch_env"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
